{
    "template": {
        "Square brackets": {
            "long_name": "Square brackets",
            "short_name": "Square brackets",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Populate field from available choices, or with free text if indicated; remove brackets and restyle text to match other text in the final document"
            ]
        },
        "Chevrons": {
            "long_name": "Chevrons",
            "short_name": "Chevrons",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "When complete, remove chevrons and restyle text to match other text in the final document"
            ]
        },
        "Sponsor Confidentiality Statement": {
            "long_name": "Enter Sponsor Confidentiality Statement",
            "short_name": "Sponsor Confidentiality Statement",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Insert the Sponsor\u2019s confidentiality statement, if applicable, otherwise delete."
            ]
        },
        "Full Title": {
            "long_name": "Enter Full Title",
            "short_name": "Full Title",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "The protocol should have a descriptive title that identifies the scientific aspects of the trial sufficiently to ensure it is immediately evident what the trial is investigating and on whom, and to allow retrieval from literature or internet searches."
            ]
        },
        "Original Protocol Indicator": {
            "long_name": "Original Protocol Indicator",
            "short_name": "Original Protocol Indicator",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "Country Identifier": {
            "long_name": "Country Identifier",
            "short_name": "Country Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "If the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope."
            ]
        },
        "Region Identifier": {
            "long_name": "Region Identifier",
            "short_name": "Region Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "If the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope."
            ]
        },
        "Site Identifier": {
            "long_name": "Enter Site Identifier",
            "short_name": "Site Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "If the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope."
            ]
        },
        "Sponsor\u2019s Investigational Product Code(s)": {
            "long_name": "Enter Sponsor\u2019s Investigational Product Code(s)",
            "short_name": "Sponsor\u2019s Investigational Product Code(s)",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Enter the Sponsor\u2019s unique identifier for investigational compound(s) in the trial. Add fields as needed."
            ]
        },
        "Nonproprietary Name(s)": {
            "long_name": "Enter Nonproprietary Name(s)",
            "short_name": "Nonproprietary Name(s)",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "Proprietary Name(s)": {
            "long_name": "Enter Proprietary Name(s)",
            "short_name": "Proprietary Name(s)",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Omit nonproprietary name fields if a nonproprietary name has not yet been assigned. Omit proprietary name fields if not yet established."
            ]
        },
        "Co-Sponsor Name": {
            "long_name": "Enter Co-Sponsor Name",
            "short_name": "Co-Sponsor Name",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "Co-Sponsor Legal Address": {
            "long_name": "Enter Co-Sponsor Legal Address",
            "short_name": "Co-Sponsor Legal Address",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Local Sponsor Name and Address:"
            ]
        },
        "FDA IND Number": {
            "long_name": "FDA IND Number",
            "short_name": "FDA IND Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "WHO/UTN Number": {
            "long_name": "WHO/UTN Number",
            "short_name": "WHO/UTN Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "Other Regulatory or Clinical Trial Identifier": {
            "long_name": "Other Regulatory or Clinical Trial Identifier",
            "short_name": "Other Regulatory or Clinical Trial Identifier",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Include all identifiers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for identifiers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed."
            ]
        },
        "State location where information can be found": {
            "long_name": "State location where information can be found",
            "short_name": "State location where information can be found",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "All versions should be uniquely identifiable. "
            ]
        },
        "describe method": {
            "long_name": "describe method",
            "short_name": "describe method",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "contact information for Medical Expert (as designated by sponsor) or state location where information can be found": {
            "long_name": "Enter contact information for Medical Expert (as designated by sponsor) or state location where information can be found",
            "short_name": "contact information for Medical Expert (as designated by sponsor) or state location where information can be found",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "#/%": {
            "long_name": "#/%",
            "short_name": "#/%",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "For a country/regional amendment, provide the estimated local or regional enrollment at the time the Sponsor approved the amendment."
            ]
        },
        "Globally/Locally/by Cohort": {
            "long_name": "Globally/Locally/by Cohort",
            "short_name": "Globally/Locally/by Cohort",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "For a country/regional amendment, provide the estimated local or regional enrollment at the time the Sponsor approved the amendment."
            ]
        },
        "Primary Reason for Amendment": {
            "long_name": "Primary Reason for Amendment",
            "short_name": "Primary Reason for Amendment",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "Secondary Reason for Amendment": {
            "long_name": "Secondary Reason for Amendment",
            "short_name": "Secondary Reason for Amendment",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "Yes/No": {
            "long_name": "Yes/No",
            "short_name": "Yes/No",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "Section # and Name of Change": {
            "long_name": "Enter Section # and Name of Change",
            "short_name": "Section # and Name of Change",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "Population type": {
            "long_name": "Population type",
            "short_name": "Population type",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Intervention model": {
            "long_name": "Intervention model",
            "short_name": "Intervention model",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Population diagnosis or condition": {
            "long_name": "Population diagnosis or condition",
            "short_name": "Population diagnosis or condition",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Control type": {
            "long_name": "Control type",
            "short_name": "Control type",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "minimum age": {
            "long_name": "minimum age",
            "short_name": "minimum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "units of minimum age": {
            "long_name": "units of minimum age",
            "short_name": "units of minimum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "maximum age": {
            "long_name": "maximum age",
            "short_name": "maximum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "units of maximum age": {
            "long_name": "units of maximum age",
            "short_name": "units of maximum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Nonproprietary name": {
            "long_name": "Nonproprietary name",
            "short_name": "Nonproprietary name",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "INN": {
            "long_name": "INN",
            "short_name": "INN",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "\u201cNot applicable\u201d": {
            "long_name": "Enter \u201cNot applicable\u201d",
            "short_name": "\u201cNot applicable\u201d",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Site distribution": {
            "long_name": "Site distribution",
            "short_name": "Site distribution",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Intervention assignment method": {
            "long_name": "Intervention assignment method",
            "short_name": "Intervention assignment method",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Master Protocol Indicator": {
            "long_name": "Master Protocol Indicator",
            "short_name": "Master Protocol Indicator",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Drug/Device Combination Product Indicator": {
            "long_name": "Drug/Device Combination Product Indicator",
            "short_name": "Drug/Device Combination Product Indicator",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "Adaptive Trial Design Indicator": {
            "long_name": "Adaptive Trial Design Indicator",
            "short_name": "Adaptive Trial Design Indicator",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "blinded roles": {
            "long_name": "blinded roles",
            "short_name": "blinded roles",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "\u201cNot applicable (No blinding)\u201d indicates an open-label trial."
            ]
        },
        "Target/Maximum": {
            "long_name": "Target/Maximum",
            "short_name": "Target/Maximum",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "randomly assigned to trial intervention/enrolled": {
            "long_name": "randomly assigned to trial intervention/enrolled",
            "short_name": "randomly assigned to trial intervention/enrolled",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "total planned duration of trial intervention": {
            "long_name": "Enter total planned duration of trial intervention",
            "short_name": "total planned duration of trial intervention",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "total planned duration of trial intervention unit of time": {
            "long_name": "total planned duration of trial intervention unit of time",
            "short_name": "total planned duration of trial intervention unit of time",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "total planned duration of trial participation": {
            "long_name": "Enter total planned duration of trial participation",
            "short_name": "total planned duration of trial participation",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "total planned duration of trial participation unit of time": {
            "long_name": "total planned duration of trial participation unit of time",
            "short_name": "total planned duration of trial participation unit of time",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "Trial-specific Intervention Risks and Mitigations": {
            "long_name": "Enter Trial-specific Intervention Risks and Mitigations",
            "short_name": "Trial-specific Intervention Risks and Mitigations",
            "optional": true,
            "section_number": "2.2.1",
            "section_title": "Risk Summary and Mitigation Strategy",
            "instructions": [
                "Trial Procedures \u2013 Describe risks associated with the design (e.g., placebo arm) and procedures specific to this trial (e.g., biopsies), and any measures to control or mitigate the risks. Provide a brief description of strategies to mitigate identified risks or provide a cross reference to the relevant protocol section. This is not intended to be an exhaustive list of all possible risks associated with trial procedures but should focus on the unique risks inherent in the design or less common or high-risk procedures. As above, provide a brief description of strategies to mitigate identified risks or provide a cross reference to the relevant protocol section."
            ]
        },
        "Trial-specific Procedure Risks and Mitigations": {
            "long_name": "Enter Trial-specific Procedure Risks and Mitigations",
            "short_name": "Trial-specific Procedure Risks and Mitigations",
            "optional": true,
            "section_number": "2.2.1",
            "section_title": "Risk Summary and Mitigation Strategy",
            "instructions": [
                "Other \u2013 Consider risks associated with other items (e.g., challenge agents, imaging agents, medical devices). This could include discussion of risk mitigation for special populations, if not described elsewhere. Insert a line for each, as needed."
            ]
        },
        "Trial-specific Other Risks and Mitigations": {
            "long_name": "Enter Trial-specific Other Risks and Mitigations",
            "short_name": "Trial-specific Other Risks and Mitigations",
            "optional": true,
            "section_number": "2.2.1",
            "section_title": "Risk Summary and Mitigation Strategy",
            "instructions": []
        },
        "Benefit Summary": {
            "long_name": "Enter Benefit Summary",
            "short_name": "Benefit Summary",
            "optional": true,
            "section_number": "2.2.2",
            "section_title": "Benefit Summary",
            "instructions": []
        },
        "Overall Risk-Benefit Assessment": {
            "long_name": "Enter Overall Risk-Benefit Assessment",
            "short_name": "Overall Risk-Benefit Assessment",
            "optional": false,
            "section_number": "2.2.3",
            "section_title": "Overall Risk-Benefit Assessment",
            "instructions": []
        },
        "Population-level Summary": {
            "long_name": "Enter Population-level Summary",
            "short_name": "Population-level Summary",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective",
            "instructions": []
        },
        "Intercurrent Event 1 Strategy": {
            "long_name": "Enter Intercurrent Event 1 Strategy",
            "short_name": "Intercurrent Event 1 Strategy",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective",
            "instructions": []
        },
        "Overall Description of Trial Design and Description of Intervention Model": {
            "long_name": "Enter Overall Description of Trial Design and Description of Intervention Model",
            "short_name": "Overall Description of Trial Design and Description of Intervention Model",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": [
                "Describe the trial duration with reference to Section 1.2 Trial Schema. Explain what the overall duration for an individual participant is anticipated to be and why, including the sequence and duration of trial periods (e.g., screening, run-in, randomisation, treatment [fixed dose/titration], follow-up/washout periods). Where applicable, include discussion of sentinel dosing (or lack thereof), dose escalation, and cohort expansion. If dose modification decisions are dependent upon review by a committee, include details in Section 11.4 Committees."
            ]
        },
        "Description of Trial Duration": {
            "long_name": "Enter Description of Trial Duration",
            "short_name": "Description of Trial Duration",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": [
                "State the method of assignment to trial intervention the level and method of blinding that will be used with reference to Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding."
            ]
        },
        "Description of Level and Method of Blinding": {
            "long_name": "Enter Description of Level and Method of Blinding",
            "short_name": "Description of Level and Method of Blinding",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": [
                "Describe any other important aspects of the design, e.g.:"
            ]
        },
        "Rationale for Estimand(s)": {
            "long_name": "Enter Rationale for Estimand(s)",
            "short_name": "Rationale for Estimand(s)",
            "optional": false,
            "section_number": "4.2.1",
            "section_title": "Rationale for Estimand(s)",
            "instructions": []
        },
        "Rationale for Intervention Model": {
            "long_name": "Enter Rationale for Intervention Model",
            "short_name": "Rationale for Intervention Model",
            "optional": false,
            "section_number": "4.2.2",
            "section_title": "Rationale for Intervention Model",
            "instructions": []
        },
        "Rationale for Control Type": {
            "long_name": "Enter Rationale for Control Type",
            "short_name": "Rationale for Control Type",
            "optional": false,
            "section_number": "4.2.3",
            "section_title": "Rationale for Control Type",
            "instructions": []
        },
        "Rationale for Adaptive or Novel Trial Design": {
            "long_name": "Enter Rationale for Adaptive or Novel Trial Design",
            "short_name": "Rationale for Adaptive or Novel Trial Design",
            "optional": false,
            "section_number": "4.2.5",
            "section_title": "Rationale for Adaptive or Novel Trial Design",
            "instructions": []
        },
        "Definitions Related to Childbearing Potential ": {
            "long_name": "Enter Definitions Related to Childbearing Potential ",
            "short_name": "Definitions Related to Childbearing Potential ",
            "optional": false,
            "section_number": "5.4.1",
            "section_title": "Definitions Related to Childbearing Potential",
            "instructions": []
        },
        "Contraception Requirements.": {
            "long_name": "Enter Contraception Requirements.",
            "short_name": "Contraception Requirements.",
            "optional": false,
            "section_number": "5.4.2",
            "section_title": "Contraception Requirements",
            "instructions": []
        },
        "Caffeine, Alcohol, Tobacco, and Other Restrictions": {
            "long_name": "Enter Caffeine, Alcohol, Tobacco, and Other Restrictions",
            "short_name": "Caffeine, Alcohol, Tobacco, and Other Restrictions",
            "optional": false,
            "section_number": "5.5.2",
            "section_title": "Caffeine, Alcohol, Tobacco, and Other Restrictions",
            "instructions": []
        },
        "description of the overview of trial interventions or a heading for the optional table below": {
            "long_name": "Enter description of the overview of trial interventions or a heading for the optional table below",
            "short_name": "description of the overview of trial interventions or a heading for the optional table below",
            "optional": false,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Select Arm Type": {
            "long_name": "Select Arm Type",
            "short_name": "Select Arm Type",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Select Intervention Type": {
            "long_name": "Select Intervention Type",
            "short_name": "Select Intervention Type",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Select Pharmaceutical Dose Form": {
            "long_name": "Select Pharmaceutical Dose Form",
            "short_name": "Select Pharmaceutical Dose Form",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Dosage Strength(s)": {
            "long_name": "Enter Dosage Strength(s)",
            "short_name": "Dosage Strength(s)",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Dosage Level(s)": {
            "long_name": "Enter Dosage Level(s)",
            "short_name": "Dosage Level(s)",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Select Route of Administration": {
            "long_name": "Select Route of Administration",
            "short_name": "Select Route of Administration",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Regimen/Treatment Period/Vaccination Regimen": {
            "long_name": "Enter Regimen/Treatment Period/Vaccination Regimen",
            "short_name": "Regimen/Treatment Period/Vaccination Regimen",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Select Use": {
            "long_name": "Select Use",
            "short_name": "Select Use",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Select IMP or NIMP": {
            "long_name": "Select IMP or NIMP",
            "short_name": "Select IMP or NIMP",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Select Sourcing": {
            "long_name": "Select Sourcing",
            "short_name": "Select Sourcing",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "Preparation of Investigational Trial Intervention ": {
            "long_name": "Enter Preparation of Investigational Trial Intervention ",
            "short_name": "Preparation of Investigational Trial Intervention ",
            "optional": false,
            "section_number": "6.6.1",
            "section_title": "{Preparation of Investigational Trial Intervention}",
            "instructions": []
        },
        "Measures to Maintain Blinding": {
            "long_name": "Enter Measures to Maintain Blinding",
            "short_name": "Measures to Maintain Blinding",
            "optional": false,
            "section_number": "6.7.3",
            "section_title": "{Measures to Maintain Blinding}",
            "instructions": []
        },
        "Investigational Trial Intervention Adherence": {
            "long_name": "Enter Investigational Trial Intervention Adherence",
            "short_name": "Investigational Trial Intervention Adherence",
            "optional": false,
            "section_number": "6.8",
            "section_title": "Investigational Trial Intervention Adherence",
            "instructions": []
        },
        "Description of Noninvestigational Trial Intervention": {
            "long_name": "Enter Description of Noninvestigational Trial Intervention",
            "short_name": "Description of Noninvestigational Trial Intervention",
            "optional": false,
            "section_number": "6.9",
            "section_title": "Description of Noninvestigational Trial Intervention",
            "instructions": []
        },
        "Background Trial Interventions": {
            "long_name": "Enter Background Trial Interventions",
            "short_name": "Background Trial Interventions",
            "optional": false,
            "section_number": "6.9.1",
            "section_title": "{Background Trial Intervention}",
            "instructions": []
        },
        "Other Noninvestigational Trial Intervention": {
            "long_name": "Enter Other Noninvestigational Trial Intervention",
            "short_name": "Other Noninvestigational Trial Intervention",
            "optional": false,
            "section_number": "6.9.3",
            "section_title": "{Other Noninvestigational Trial Intervention}",
            "instructions": []
        },
        "Permitted Concomitant Therapy": {
            "long_name": "Enter Permitted Concomitant Therapy",
            "short_name": "Permitted Concomitant Therapy",
            "optional": false,
            "section_number": "6.10.2",
            "section_title": "{Permitted Concomitant Therapy}",
            "instructions": []
        },
        "Management of Loss to Follow-Up": {
            "long_name": "Enter Management of Loss to Follow-Up",
            "short_name": "Management of Loss to Follow-Up",
            "optional": false,
            "section_number": "7.3",
            "section_title": "Management of Loss to Follow-Up",
            "instructions": []
        },
        "Clinical Laboratory Assessments": {
            "long_name": "Enter Clinical Laboratory Assessments",
            "short_name": "Clinical Laboratory Assessments",
            "optional": false,
            "section_number": "8.4.4",
            "section_title": "{Clinical Laboratory Assessments}",
            "instructions": []
        },
        "Definitions of Product Complaints": {
            "long_name": "Enter Definitions of Product Complaints",
            "short_name": "Definitions of Product Complaints",
            "optional": false,
            "section_number": "9.1.3",
            "section_title": "Definitions of Product Complaints",
            "instructions": []
        },
        "Timing for reporting to Sponsor or Designee": {
            "long_name": "Timing for reporting to Sponsor or Designee",
            "short_name": "Timing for reporting to Sponsor or Designee",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "Event Collection and Reporting Timing": {
            "long_name": "Enter Event Collection and Reporting Timing",
            "short_name": "Event Collection and Reporting Timing",
            "optional": false,
            "section_number": "9.2.1",
            "section_title": "Timing",
            "instructions": []
        },
        "Follow-up": {
            "long_name": "Enter Follow-up",
            "short_name": "Follow-up",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "Disease-related Events or Outcomes not Qualifying as AEs or SAEs": {
            "long_name": "Enter Disease-related Events or Outcomes not Qualifying as AEs or SAEs",
            "short_name": "Disease-related Events or Outcomes not Qualifying as AEs or SAEs",
            "optional": false,
            "section_number": "9.2.5",
            "section_title": "Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
            "instructions": []
        },
        "Participants Whose Partners Become Pregnant During the Trial": {
            "long_name": "Enter Participants Whose Partners Become Pregnant During the Trial",
            "short_name": "Participants Whose Partners Become Pregnant During the Trial",
            "optional": false,
            "section_number": "9.3.2",
            "section_title": "{Participants Whose Partners Become Pregnant During the Trial}",
            "instructions": []
        },
        "Statistical Analysis Method": {
            "long_name": "Enter Statistical Analysis Method",
            "short_name": "Statistical Analysis Method",
            "optional": false,
            "section_number": "10.5.1.1",
            "section_title": "{Statistical Analysis Method}",
            "instructions": []
        },
        "Handling of Data in Relation to Primary Estimand(s)": {
            "long_name": "Enter Handling of Data in Relation to Primary Estimand(s)",
            "short_name": "Handling of Data in Relation to Primary Estimand(s)",
            "optional": false,
            "section_number": "10.4.1.2",
            "section_title": "Handling of Data in Relation to Primary Estimand(s)",
            "instructions": []
        },
        "Handling of Missing Data in Relation to Primary Estimand(s)": {
            "long_name": "Enter Handling of Missing Data in Relation to Primary Estimand(s)",
            "short_name": "Handling of Missing Data in Relation to Primary Estimand(s)",
            "optional": false,
            "section_number": "10.4.1.3",
            "section_title": "Handling of Missing Data in Relation to Primary Estimand(s)",
            "instructions": []
        },
        "Handling of Data in Relation to Secondary Estimand(s)": {
            "long_name": "Enter Handling of Data in Relation to Secondary Estimand(s)",
            "short_name": "Handling of Data in Relation to Secondary Estimand(s)",
            "optional": false,
            "section_number": "10.5.1.2",
            "section_title": "{Handling of Data in Relation to Secondary Estimand(s)}",
            "instructions": []
        },
        "Handling of Missing Data in Relation to Secondary Estimand(s)": {
            "long_name": "Enter Handling of Missing Data in Relation to Secondary Estimand(s)",
            "short_name": "Handling of Missing Data in Relation to Secondary Estimand(s)",
            "optional": false,
            "section_number": "10.5.1.3",
            "section_title": "{Handling of Missing Data in Relation to Secondary Estimand(s)}",
            "instructions": []
        },
        "Sensitivity ": {
            "long_name": "Enter Sensitivity ",
            "short_name": "Sensitivity ",
            "optional": false,
            "section_number": "10.5.1.4",
            "section_title": "{Sensitivity }",
            "instructions": []
        },
        "Supplementary ": {
            "long_name": "Enter Supplementary ",
            "short_name": "Supplementary ",
            "optional": false,
            "section_number": "10.5.1.5",
            "section_title": "{Supplementary }",
            "instructions": []
        },
        "Analyses Associated with the Exploratory Objective(s)": {
            "long_name": "Enter Analyses Associated with the Exploratory Objective(s)",
            "short_name": "Analyses Associated with the Exploratory Objective(s)",
            "optional": false,
            "section_number": "10.6",
            "section_title": "Analyses Associated with the Exploratory Objective(s)",
            "instructions": []
        },
        "Informed Consent for Rescreening": {
            "long_name": "Enter Informed Consent for Rescreening",
            "short_name": "Informed Consent for Rescreening",
            "optional": false,
            "section_number": "11.3.1",
            "section_title": "{Informed Consent for Rescreening}",
            "instructions": []
        },
        "Informed Consent for Use of Remaining Samples in Exploratory Research": {
            "long_name": "Enter Informed Consent for Use of Remaining Samples in Exploratory Research",
            "short_name": "Informed Consent for Use of Remaining Samples in Exploratory Research",
            "optional": false,
            "section_number": "11.3.2",
            "section_title": "{Informed Consent for Use of Remaining Samples in Exploratory Research}",
            "instructions": []
        },
        "Risk-Based Quality Management": {
            "long_name": "Enter Risk-Based Quality Management",
            "short_name": "Risk-Based Quality Management",
            "optional": false,
            "section_number": "11.6",
            "section_title": "Risk-Based Quality Management",
            "instructions": []
        },
        "Data Protection": {
            "long_name": "Enter Data Protection",
            "short_name": "Data Protection",
            "optional": false,
            "section_number": "11.8",
            "section_title": "Data Protection",
            "instructions": []
        },
        "Identification of Source Data": {
            "long_name": "Enter Identification of Source Data",
            "short_name": "Identification of Source Data",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "Data Dissemination": {
            "long_name": "Enter Data Dissemination",
            "short_name": "Data Dissemination",
            "optional": false,
            "section_number": "11.12",
            "section_title": "Data Dissemination",
            "instructions": []
        },
        "Country/Region Identifier": {
            "long_name": "Country/Region Identifier",
            "short_name": "Country/Region Identifier",
            "optional": true,
            "section_number": "12.2",
            "section_title": "Country/Region-Specific Differences",
            "instructions": []
        },
        "Country/Region Specific Requirements": {
            "long_name": "Enter Country/Region Specific Requirements",
            "short_name": "Country/Region Specific Requirements",
            "optional": true,
            "section_number": "12.2",
            "section_title": "Country/Region-Specific Differences",
            "instructions": []
        },
        "Country/Region Specific Protocol Clarifications": {
            "long_name": "Enter Country/Region Specific Protocol Clarifications",
            "short_name": "Country/Region Specific Protocol Clarifications",
            "optional": true,
            "section_number": "12.2",
            "section_title": "Country/Region-Specific Differences",
            "instructions": []
        },
        "Sponsor Approval Date": {
            "long_name": "Enter Sponsor Approval Date",
            "short_name": "Sponsor Approval Date",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "# or % enrolled globally/locally/per cohort": {
            "long_name": "Enter # or % enrolled globally/locally/per cohort",
            "short_name": "# or % enrolled globally/locally/per cohort",
            "optional": true,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "specify alternative location": {
            "long_name": "specify alternative location",
            "short_name": "specify alternative location",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": [
                "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first)."
            ]
        },
        "enter amendment number": {
            "long_name": "enter amendment number",
            "short_name": "enter amendment number",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": [
                "(Add lines as needed)"
            ]
        },
        "enter date": {
            "long_name": "enter date",
            "short_name": "enter date",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": [
                "(Add lines as needed)"
            ]
        }
    },
    "technical": {
        "Sponsor Confidentiality Statement ": {
            "name": "Sponsor Confidentiality Statement ",
            "data_type": "Text",
            "definition": "C181236\nFor review purpose, see definition of the controlled terminology below:\nA written message within the study protocol that asserts a statement of non-disclosure, such that information contained within the protocol document may only be shared with authorized parties.",
            "guidance": "Insert the Sponsor\u2019s confidentiality statement, if applicable, otherwise delete.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: C181236",
            "repeating": "No",
            "ct": []
        },
        "Full Title ": {
            "name": "Full Title ",
            "data_type": "Text",
            "definition": "C132346\nFor review purpose, see definition of the controlled terminology below:\nThe formal descriptive name for the protocol sufficient to describe key elements of the study, aimed at a scientific audience.",
            "guidance": "The protocol should have a descriptive title that identifies the scientific aspects of the trial sufficiently to ensure it is immediately evident what the trial is investigating and on whom, and to allow retrieval from literature or internet searches.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "Title page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: C132346",
            "repeating": "No",
            "ct": []
        },
        "Country Identifier or Region Identifier or Site Identifier": {
            "name": "Country Identifier or Region Identifier or Site Identifier",
            "data_type": "Valid Value",
            "definition": "C20108\nCNEW\nCNEW\n\nFor review purpose, see definition of the controlled terminology below\nC20108\nA sequence of characters used to identify and/or name the country.\nCNEW\nA sequence of characters used to identify and/or name the region\nCNEW\nA sequence of characters used to identify and/or name the study site.",
            "guidance": "Leave blank for original protocol.\nIf the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope.",
            "conformance": "Conditional: when not global",
            "cardinality": "One to one; Many to Amendment Scope; One to Amendment Identifier; One to Protocol Identifier ",
            "relationship": "Title Page",
            "value": "Country specific: [Country Identifier] (ISO 3166 Country Codes, Alpha 3; ISO 3166 \nCountry Codes, Alpha 2)\nor\nRegion Specific: [Region Identifier]\nor\nSite specific: [Site Identifier] (Text)\nSite Identifier Text\nCondition Blank for Original Protocol Indicator = yes",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Amendment Scope, Amendment Identifier\nConcept: C20108, CNEW, CNEW",
            "repeating": "Yes, repeatable in 12.2 country/region-specific differences",
            "ct": []
        },
        "": {
            "name": "",
            "data_type": "Number",
            "definition": "N/A",
            "guidance": "Add criteria as needed.  the criteria sequentially",
            "conformance": "Required",
            "cardinality": "One to many",
            "relationship": "5.3",
            "value": "# is an identifier <criterion identifier> unique number and not replaceable",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.3 Exclusion Criteria\nConcept: Sequential number",
            "repeating": "Yes. number consecutively, repeatable for each exclusion criteria, if deleted do not replace, do not duplicate",
            "ct": []
        },
        "Nonproprietary Names": {
            "name": "Nonproprietary Names",
            "data_type": "Text",
            "definition": "C97054\nFor review purpose, see definition of the controlled terminology below\nDrug name that is not protected by a trademark, usually descriptive of its chemical structure. ",
            "guidance": "Omit nonproprietary name fields if a nonproprietary name has not yet been assigned.",
            "conformance": "Optional; Blank ",
            "cardinality": "One to many; Many to ; Many to Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text for example WHO INN, USAN, JAN, XEVMPD",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: C97054",
            "repeating": "Yes, repeatable for each nonproprietary name \n",
            "ct": []
        },
        "Proprietary Names": {
            "name": "Proprietary Names",
            "data_type": "Text",
            "definition": "C71898\nFor review purpose, see definition of the controlled terminology below\nA commercial name granted by a naming authority for use in marketing an experimental intervention.",
            "guidance": "Omit proprietary name fields if not yet established.",
            "conformance": "Optional; Blank",
            "cardinality": "One to many; Many to ; Many to Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier; \nConcept: C71898",
            "repeating": "Yes, repeatable for each proprietary name",
            "ct": []
        },
        "CoSponsor Name": {
            "name": "CoSponsor Name",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) of the trial co-Sponsor.",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
            "conformance": "Optional ",
            "cardinality": "One to one, One to Sponsor Name, One to Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name, Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "CoSponsor Legal Address": {
            "name": "CoSponsor Legal Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the trial co-sponsor.",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field\n",
            "conformance": "Optional ",
            "cardinality": "One to one; One to Heading; One to Co-Sponsor Name",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Co- Sponsor Name\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "WHOUTN Number": {
            "name": "WHOUTN Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the World Health Organisation's International Clinical Trial's Registry Platform (ICTRP).",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page ",
            "value": "UTN/WHO: Uxxxx-xxxx-xxxx with X being an integer",
            "business_rules": "Value Allowed: Yes; \nRelationship: Heading; Protocol Identifier; \nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Other Regulatory Identifier": {
            "name": "Other Regulatory Identifier",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below \nA sequence of characters used to identify a clinical trial, that is different than the one(s) previously specified or mentioned.",
            "guidance": "Include all that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW",
            "repeating": "Yes, repeatable for each regulatory agency identifier",
            "ct": []
        },
        "Approval Date or State location where Information can be found ": {
            "name": "Approval Date or State location where Information can be found ",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below \nThe date that the sponsor approved the current version of the protocol, or the physical or virtual location of the date on which the sponsor approved the current version of the protocol.",
            "guidance": "All versions should be uniquely identifiable. ",
            "conformance": "Required",
            "cardinality": "One to one; One to Protocol Identifier; One to Original Protocol One to Amendment Identifier",
            "relationship": "Title Page",
            "value": "Sponsor Approval Date (C132352)\nLocation of Sponsor Approval Date (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier, Protocol Amendment\nConcept: CNEW",
            "repeating": "Yes, reuse to approval date in Section 12.3",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Sponsor Approval Response",
                    "definition": "A terminology value set relevant to the sponsor approval responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C132352",
                    "preferred_term": "Sponsor Approval Date",
                    "definition": "The date that the sponsor approved the current version of the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Location of Sponsor Approval Date",
                    "definition": "The physical or virtual location of the date on which the sponsor approved the current version of the protocol. "
                }
            ]
        },
        "sponsor signature block name and title of sponsor signatory and signature date or This protocol was approved via describe method": {
            "name": "sponsor signature block name and title of sponsor signatory and signature date or This protocol was approved via describe method",
            "data_type": "Valid Value ",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA block of text containing the name and signature of the sponsor's signatory, along with a signature date, or a statement on behalf of the sponsor that describes the method of protocol approval.",
            "guidance": "Include either the Sponsor signature or the statement below.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "Title Page",
            "value": "Sponsor Signature Block (CNEW)\n OR \nSponsor Protocol Approval Statement (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Sponsor Signatory Response",
                    "definition": "A terminology value set relevant to the sponsor signatory responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Sponsor Signature Block",
                    "definition": "A block of text containing the name and signature of the sponsor's signatory, along with the signature date."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Sponsor Protocol Approval Statement",
                    "definition": "A statement that the protocol was approved by a method as described. This protocol was approved via <describe method>"
                }
            ]
        },
        "Describe Method": {
            "name": "Describe Method",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe narrative text describing the technique used to approve the protocol.",
            "guidance": "Include either the Sponsor signature or the statement below.",
            "conformance": "Conditional if Sponsor Protocol Approval Statement",
            "cardinality": "One to Sponsor Protocol Approval Statement",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Sponsor Protocol Approval Statement\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "contact information for Medical Expert as designated by sponsor or state location where information can be found": {
            "name": "contact information for Medical Expert as designated by sponsor or state location where information can be found",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe contact information for the sponsor's representative who can advise on specific trial-related medical questions or problems.",
            "guidance": "N/A",
            "conformance": "",
            "cardinality": "One to one; One to Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Medical Expert Contact Response\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Amendment Details": {
            "name": "Amendment Details",
            "data_type": "Valid Value ",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA written message within the study protocol that describes the amendment details, especially as to whether the protocol has been amended previously.",
            "guidance": "Choose the applicable statement below. For an original protocol that has not been amended, retain the first sentence below and delete the remainder of this entire section.\n{Not applicable. This protocol has not been amended.}\nOr include the below as applicable.\n{This protocol has been amended previously. Details of prior amendments are presented in Section 12.3 Prior Protocol Amendment(s).}",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "Amendment Details",
            "value": "Not applicable. This protocol has not been amended. (CNEW)\n\nOR\nThis protocol has been amended previously. Details of prior amendments are presented in Prior Protocol Amendment(s). (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Amendment Details Statement Response",
                    "definition": "A terminology value set relevant to the amendment details statement responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not applicable. This protocol has not been amended.",
                    "definition": "Not applicable. This protocol has not been amended."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "This protocol has been amended previously. Details of prior amendments are presented in Prior Protocol Amendment(s).",
                    "definition": "This protocol has been amended previously. Details of prior amendments are presented in Prior Protocol Amendment(s)."
                }
            ]
        },
        "The table below describes the current amendment": {
            "name": "The table below describes the current amendment",
            "data_type": "Text",
            "definition": "N/A",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "Amendment Details",
            "value": "",
            "business_rules": "Value Allowed: No\nRelationship: Current Amendment\nConcept: Required text",
            "repeating": "No",
            "ct": []
        },
        "Approximately  enrolled GloballyLocallyby Cohort": {
            "name": "Approximately  enrolled GloballyLocallyby Cohort",
            "data_type": "Text",
            "definition": "C68846\nCNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
            "guidance": "",
            "conformance": "Optional",
            "cardinality": "One to one; One to amendment number",
            "relationship": "Amendment Details",
            "value": "Approximate <#/%> enrolled <Globally/Locally/by Cohort>",
            "business_rules": "Value Allowed: Yes\nRelationship: Statement\nConcept: C68846, CNEW",
            "repeating": "Yes, reuse to Section 12.3 ",
            "ct": []
        },
        "Number or ": {
            "name": "Number or ",
            "data_type": "Number",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
            "guidance": "",
            "conformance": " if Original Protocol =No",
            "cardinality": "One to Amendment Number",
            "relationship": "Amendment Details",
            "value": "Integer for Number or one decimal point for percent",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Row Heading, Statement\nConcept: CNEW",
            "repeating": "Yes, reuse to section 12.3",
            "ct": []
        },
        "Other description": {
            "name": "Other description",
            "data_type": "Text",
            "definition": "C17649\nFor review purpose, see definition of the controlled terminology below\nDifferent than the one(s) previously specified or mentioned. ",
            "guidance": "Choose from the available categories as the primary reason and secondary reason(s) for the amendment. Select the closest match among the choices. Changes to primary estimand, endpoints, or related measures should be listed as a change of strategy. If none of the choices apply, choose \u201cother\u201d and provide a description. If no secondary reason, indicate \u201cnot applicable\u201d for the secondary reason.",
            "conformance": "Conditionalif Other is selected as a Valid Value",
            "cardinality": "One to one",
            "relationship": "Amendment Details",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Secondary reason, Protocol Identifier, Protocol Amendment\nConcept:C17649",
            "repeating": "No",
            "ct": []
        },
        "YesNo": {
            "name": "YesNo",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the amendment likely to have a substantial impact on the reliability and robustness of the data generated in the clinical trial.",
            "guidance": "N/A\n",
            "conformance": "Conditional: if there is an amendment",
            "cardinality": "One to one; One to Amendment Identifier; One to Protocol Identifier",
            "relationship": "Amendment Details",
            "value": "Yes (C49488), No (C49487)",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Amendment Identifier, Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66742",
                    "preferred_term": "NY",
                    "definition": "A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable."
                },
                {
                    "ncit_code": "C49487",
                    "preferred_term": "No",
                    "definition": "The non-affirmative response to a question."
                },
                {
                    "ncit_code": "C49488",
                    "preferred_term": "Yes",
                    "definition": "The affirmative response to a question."
                }
            ]
        },
        "If yes briefly explain": {
            "name": "If yes briefly explain",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short descriptive account of any substantial impacts on the reliability and robustness of the data generated in the clinical trial due to the protocol amendment.",
            "guidance": "Briefly Explain Substantial Impact on Data",
            "conformance": "Conditional: if there is an amendment and if the answer to \"Is this amendment likely to have a substantial impact on the reliability and robustness of the data generated in the clinical trial?\" is yes",
            "cardinality": "One to amendment identifier",
            "relationship": "Amendment Details",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Amendment Identifier, Protocol Identifier\nWhen the value is yes there is a text response for explanation\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Section  and Name of Change ": {
            "name": "Section  and Name of Change ",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe protocol section number and name containing the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional:",
            "cardinality": "One to Column Heading\nRow description of change \nDescription of Change, Rational for Amendment Change",
            "relationship": "12.3",
            "value": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
            "business_rules": "Value Allowed: Yes\nRelationship: Description of Change\n",
            "repeating": "Yes, repeatable for every Description of Change",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Protocol Number and Name Response",
                    "definition": "A terminology value set relevant to the protocol number and name responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1 PROTOCOL SUMMARY",
                    "definition": "Section 1 of the ICH M11 Protocol standard, PROTOCOL SUMMARY."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.1 Protocol Synopsis",
                    "definition": "Section 1.1 of the ICH M11 Protocol standard, Protocol Synopsis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.1.1 Primary and Secondary Objectives and Estimands",
                    "definition": "Section 1.1.1 of the ICH M11 Protocol standard, Primary and Secondary Objectives and Estimands."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.1.2 Overall Design",
                    "definition": "Section 1.1.2 of the ICH M11 Protocol standard, Overall Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.2 Trial Schema",
                    "definition": "Section 1.2 of the ICH M11 Protocol standard, Trial Schema."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.3 Schedule of Activities",
                    "definition": "Section 1.3 of the ICH M11 Protocol standard, Schedule of Activities."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2 INTRODUCTION",
                    "definition": "Section 2 of the ICH M11 Protocol standard, INTRODUCTION."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.1 Purpose of Trial",
                    "definition": "Section 2.1 of the ICH M11 Protocol standard, Purpose of Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "",
                    "definition": "Section 2.2 of the ICH M11 Protocol standard, Summary of Benefits and Risks."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.2.1 ",
                    "definition": "Section 2.2.1 of the ICH M11 Protocol standard, ."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.2.2  Summary",
                    "definition": "Section 2.2.2 of the ICH M11 Protocol standard,  Summary."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.2.3 Overall Risk ",
                    "definition": "Section 2.2.3 of the ICH M11 Protocol standard, Overall Benefit ."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3 TRIAL OBJECTIVES AND ESTIMANDS",
                    "definition": "Section 3 of the ICH M11 Protocol standard, TRIAL OBJECTIVES AND ESTIMANDS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.1 Primary Objective(s) and Associated Estimand(s)",
                    "definition": "Section 3.1 of the ICH M11 Protocol standard, Primary Objective(s) and Associated Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.1.1 Primary ",
                    "definition": "Section 3.1.1 of the ICH M11 Protocol standard, Primary ."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.2 Secondary Objective(s) and Associated Estimand(s)",
                    "definition": "Section 3.2 of the ICH M11 Protocol standard, Secondary Objective(s) and Associated Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.3 Exploratory Objective(s)",
                    "definition": "Section 3.3 of the ICH M11 Protocol standard, Exploratory Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4 TRIAL DESIGN",
                    "definition": "Section 4 of the ICH M11 Protocol standard, TRIAL DESIGN."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.1 Description of Trial Design",
                    "definition": "Section 4.1 of the ICH M11 Protocol standard, Description of Trial Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.1.1 Stakeholder Input into Design",
                    "definition": "Section 4.1.1 of the ICH M11 Protocol standard, Stakeholder Input into Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2 Rationale for Trial Design",
                    "definition": "Section 4.2 of the ICH M11 Protocol standard, Rationale for Trial Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.1 Rationale for Intervention Model",
                    "definition": "Section 4.2.1 of the ICH M11 Protocol standard, Rationale for Intervention Model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.2 Rationale for Duration",
                    "definition": "Section 4.2.2 of the ICH M11 Protocol standard, Rationale for Duration."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.3 Rationale for Estimands",
                    "definition": "Section 4.2.3 of the ICH M11 Protocol standard, Rationale for Estimands."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.4 Rationale for Interim Analysis",
                    "definition": "Section 4.2.4 of the ICH M11 Protocol standard, Rationale for Interim Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.5 Rationale for Control Type",
                    "definition": "Section 4.2.5 of the ICH M11 Protocol standard, Rationale for Control Type."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.6 Rationale for Adaptive or Novel Trial Design",
                    "definition": "Section 4.2.6 of the ICH M11 Protocol standard, Rationale for Adaptive or Novel Trial Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.7 Rationale for Other Trial Design Aspects",
                    "definition": "Section 4.2.7 of the ICH M11 Protocol standard, Rationale for Other Trial Design Aspects."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.3 Trial Stopping Rules",
                    "definition": "Section 4.3 of the ICH M11 Protocol standard, Trial Stopping Rules."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.4 Start of Trial and End of Trial",
                    "definition": "Section 4.4 of the ICH M11 Protocol standard, Start of Trial and End of Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.5 Access to Trial Intervention After End of Trial",
                    "definition": "Section 4.5 of the ICH M11 Protocol standard, Access to Trial Intervention After End of Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5 TRIAL POPULATION",
                    "definition": "Section 5 of the ICH M11 Protocol standard, TRIAL POPULATION."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.1 Description of Trial Population and Rationale",
                    "definition": "Section 5.1 of the ICH M11 Protocol standard, Description of Trial Population and Rationale."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.2 Inclusion Criteria",
                    "definition": "Section 5.2 of the ICH M11 Protocol standard, Inclusion Criteria."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.3 Exclusion Criteria",
                    "definition": "Section 5.3 of the ICH M11 Protocol standard, Exclusion Criteria."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.4 Contraception",
                    "definition": "Section 5.4 of the ICH M11 Protocol standard, Contraception."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.4.1 Definitions Related to Childbearing Potential",
                    "definition": "Section 5.4.1 of the ICH M11 Protocol standard, Definitions Related to Childbearing Potential."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.4.2 Contraception Requirements",
                    "definition": "Section 5.4.2 of the ICH M11 Protocol standard, Contraception Requirements."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5 Lifestyle Restrictions",
                    "definition": "Section 5.5 of the ICH M11 Protocol standard, Lifestyle Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.1 Meals and Dietary Restrictions",
                    "definition": "Section 5.5.1 of the ICH M11 Protocol standard, Contraception Requirements."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.2 Caffeine, Alcohol, Tobacco, and Other Restrictions",
                    "definition": "Section 5.5.2 of the ICH M11 Protocol standard, Caffeine, Alcohol, Tobacco, and Other Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.3 Physical Activity Restrictions",
                    "definition": "Section 5.5.3 of the ICH M11 Protocol standard, Physical Activity Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.4 Other Activity Restrictions",
                    "definition": "Section 5.5.4 of the ICH M11 Protocol standard, Other Activity Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.6 Screen Failure and Rescreening",
                    "definition": "Section 5.6 of the ICH M11 Protocol standard, Screen Failure and Rescreening."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6 TRIAL INTERVENTION AND CONCOMITANT THERAPY",
                    "definition": "Section 6 of the ICH M11 Protocol standard, TRIAL INTERVENTION AND CONCOMITANT THERAPY."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.1 Description of Investigational Trial Intervention",
                    "definition": "Section 6.1 of the ICH M11 Protocol standard, Overview of Trial Interventions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.2 Description of Investigational Trial Intervention",
                    "definition": "Section 6.2 of the ICH M11 Protocol standard, Description of Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.3 Rationale for Investigation Trial Intervention Dose and Regimen",
                    "definition": "Section 6.3 of the ICH M11 Protocol standard, Rationale for Investigation Trial Intervention Dose and Regimen."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.4 Investigational Trial Intervention Administration",
                    "definition": "Section 6.4 of the ICH M11 Protocol standard, Investigational Trial Intervention Administration."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.5 Investigational Trial Intervention Dose Modification",
                    "definition": "Section 6.5 of the ICH M11 Protocol standard, Investigational Trial Intervention Dose Modification."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.6 Management of Investigational Trial Intervention Overdose",
                    "definition": "Section 6.6 of the ICH M11 Protocol standard, Management of Investigational Trial Intervention Overdose."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7 Preparation, Storage, Handling and Accountability of Investigational Trial Intervention(s)",
                    "definition": "Section 6.7 of the ICH M11 Protocol standard, Preparation, Storage, Handling and Accountability of Investigational Trial Intervention(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7.1 Preparation of Investigational Trial Intervention(s)",
                    "definition": "Section 6.7.1 of the ICH M11 Protocol standard, Preparation of Investigational Trial Intervention(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7.2 Storage and Handling of Investigational Trial Intervention",
                    "definition": "Section 6.7.2 of the ICH M11 Protocol standard, Storage and Handling of Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7.3 Accountability of Investigational Trial Intervention",
                    "definition": "Section 6.7.3 of the ICH M11 Protocol standard, Accountability of Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8 Investigational Trial Intervention Assignment, Randomisation and Blinding",
                    "definition": "Section 6.8 of the ICH M11 Protocol standard, Investigational Trial Intervention Assignment, Randomisation and Blinding."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.1 Participant Assignment to Investigational Trial Intervention",
                    "definition": "Section 6.8.1 of the ICH M11 Protocol standard, Participant Assignment to Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.2 Randomisation",
                    "definition": "Section 6.8.2 of the ICH M11 Protocol standard, Randomisation."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.3 Blinding",
                    "definition": "Section 6.8.3 of the ICH M11 Protocol standard, Blinding."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.4 Emergency Unblinding at the Site",
                    "definition": "Section 6.8.4 of the ICH M11 Protocol standard, Emergency Unblinding at the Site."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.9 Investigational Trial Intervention Compliance",
                    "definition": "Section 6.9 of the ICH M11 Protocol standard, Investigational Trial Intervention Compliance."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10 Description of Non-Investigational Trial Intervention(s)",
                    "definition": "Section 6.1 of the ICH M11 Protocol standard, Description of Non-Investigational Trial Intervention(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10.1 Background Intervention",
                    "definition": "Section 6.10.1 of the ICH M11 Protocol standard, Background Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10.2 Rescue Therapy",
                    "definition": "Section 6.10.2 of the ICH M11 Protocol standard, Rescue Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10.3 Other Non-investigational Intervention",
                    "definition": "Section 6.10.3 of the ICH M11 Protocol standard, Other Non-investigational Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.11 Concomitant Therapy",
                    "definition": "Section 6.11 of the ICH M11 Protocol standard, Concomitant Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.11.1 Prohibited Concomitant Therapy",
                    "definition": "Section 6.11.1 of the ICH M11 Protocol standard, Prohibited Concomitant Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.11.2 Permitted Concomitant Therapy",
                    "definition": "Section 6.11.2 of the ICH M11 Protocol standard, Permitted Concomitant Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7 PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL",
                    "definition": "Section 7 of the ICH M11 Protocol standard, PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1 Discontinuation of Trial Intervention for Individual Participants",
                    "definition": "Section 7.1 of the ICH M11 Protocol standard, Discontinuation of Trial Intervention for Individual Participants."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1.1 Permanent Discontinuation of Trial Intervention",
                    "definition": "Section 7.1.1 of the ICH M11 Protocol standard, Permanent Discontinuation of Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1.2 Temporary Discontinuation of Trial Intervention",
                    "definition": "Section 7.1.2 of the ICH M11 Protocol standard, Temporary Discontinuation of Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1.3 Rechallenge",
                    "definition": "Section 7.1.3 of the ICH M11 Protocol standard, Rechallenge."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.2 Discontinuation or Withdrawal from the Trial",
                    "definition": "Section 7.2 of the ICH M11 Protocol standard, Discontinuation or Withdrawal from the Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.3 Lost to Follow-Up",
                    "definition": "Section 7.3 of the ICH M11 Protocol standard, Lost to Follow-Up."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8 TRIAL ASSESSMENTS AND PROCEDURES",
                    "definition": "Section 8 of the ICH M11 Protocol standard, TRIAL ASSESSMENTS AND PROCEDURES."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.1 Trial Assessments and Procedures Considerations",
                    "definition": "Section 8.1 of the ICH M11 Protocol standard, Trial Assessments and Procedures Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.2 Screening/Baseline Assessments and Procedures",
                    "definition": "Section 8.2 of the ICH M11 Protocol standard, Screening/Baseline Assessments and Procedures."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.3 Efficacy Assessments and Procedures",
                    "definition": "Section 8.3 of the ICH M11 Protocol standard, Efficacy Assessments and Procedures."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4 Safety Assessments and Procedures",
                    "definition": "Section 8.4 of the ICH M11 Protocol standard, Safety Assessments and Procedures."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.1 Physical Examination",
                    "definition": "Section 8.4.1 of the ICH M11 Protocol standard, Physical Examination."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.2 Vital Signs",
                    "definition": "Section 8.4.2 of the ICH M11 Protocol standard, Vital Signs."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.3 Electrocardiograms",
                    "definition": "Section 8.4.3 of the ICH M11 Protocol standard, Electrocardiograms."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.4 Clinical Laboratory Assessments",
                    "definition": "Section 8.4.4 of the ICH M11 Protocol standard, Clinical Laboratory Assessments."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.5 Pregnancy Testing",
                    "definition": "Section 8.4.5 of the ICH M11 Protocol standard, Pregnancy Testing."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.6 Suicidal Ideation and Behaviour Risk Monitoring",
                    "definition": "Section 8.4.6 of the ICH M11 Protocol standard, Suicidal Ideation and Behaviour Risk Monitoring."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.5 Pharmacokinetics",
                    "definition": "Section 8.5 of the ICH M11 Protocol standard, Pharmacokinetics."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6 Biomarkers",
                    "definition": "Section 8.6 of the ICH M11 Protocol standard, Biomarkers."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6.1 Genetics and Pharmacogenomics",
                    "definition": "Section 8.6.1 of the ICH M11 Protocol standard, Genetics and Pharmacogenomics."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6.2 Pharmacodynamic Biomarkers",
                    "definition": "Section 8.6.2 of the ICH M11 Protocol standard, Pharmacodynamic Biomarkers."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6.3 Other Biomarkers",
                    "definition": "Section 8.6.3 of the ICH M11 Protocol standard, Other Biomarkers."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.7 Immunogenicity Assessments",
                    "definition": "Section 8.7 of the ICH M11 Protocol standard, Immunogenicity Assessments."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.8 Medical Resource Utilisation and Health Economics",
                    "definition": "Section 8.8 of the ICH M11 Protocol standard, Medical Resource Utilisation and Health Economics."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9 ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION",
                    "definition": "Section 9 of the ICH M11 Protocol standard, ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1 Definitions",
                    "definition": "Section 9.1 of the ICH M11 Protocol standard, Definitions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1.1 Definitions of Adverse Events",
                    "definition": "Section 9.1.1 of the ICH M11 Protocol standard, Definitions of Adverse Events."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1.2 Definitions of Serious Adverse Events",
                    "definition": "Section 9.1.2 of the ICH M11 Protocol standard, Definitions of Serious Adverse Events."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1.3 Definition of Medical Device Product Complaints",
                    "definition": "Section 9.1.3 of the ICH M11 Protocol standard, Definition of Medical Device Product Complaints."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.2 Timing and Mechanism for Collection and Reporting",
                    "definition": "Section 9.2 of the ICH M11 Protocol standard, Timing and Mechanism for Collection and Reporting."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3 Identification, Recording and Follow-Up",
                    "definition": "Section 9.3 of the ICH M11 Protocol standard, Identification, Recording and Follow-Up."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.1 Identification",
                    "definition": "Section 9.3.1 of the ICH M11 Protocol standard, Identification."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.2 Severity",
                    "definition": "Section 9.3.2 of the ICH M11 Protocol standard, Severity."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.3 Causality",
                    "definition": "Section 9.3.3 of the ICH M11 Protocol standard, Causality."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.4 Follow-up",
                    "definition": "Section 9.3.4 of the ICH M11 Protocol standard, Follow-up."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4 Reporting",
                    "definition": "Section 9.4 of the ICH M11 Protocol standard, Reporting."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4.1 Regulatory Reporting Requirements",
                    "definition": "Section 9.4.1 of the ICH M11 Protocol standard, Regulatory Reporting Requirements."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4.2 Adverse Events of Special Interest",
                    "definition": "Section 9.4.2 of the ICH M11 Protocol standard, Adverse Events of Special Interest."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4.3 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
                    "definition": "Section 9.4.3 of the ICH M11 Protocol standard, Disease-related Events or Outcomes Not Qualifying as AEs or SAEs."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.5 Pregnancy and Postpartum Information",
                    "definition": "Section 9.5 of the ICH M11 Protocol standard, Pregnancy and Postpartum Information."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.5.1 Participants Who Become Pregnant During the Trial",
                    "definition": "Section 9.5.1 of the ICH M11 Protocol standard, Participants Who Become Pregnant During the Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.5.2 Participants Whose Partners Become Pregnant",
                    "definition": "Section 9.5.2 of the ICH M11 Protocol standard, Participants Whose Partners Become Pregnant."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10 Statistical Considerations",
                    "definition": "Section 10 of the ICH M11 Protocol standard, Statistical Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.1 General Considerations",
                    "definition": "Section 10.1 of the ICH M11 Protocol standard, General Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.2 Analysis Sets",
                    "definition": "Section 10.2 of the ICH M11 Protocol standard, Analysis Sets."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.3 Analyses of Demographics and Other Baseline Variables",
                    "definition": "Section 10.3 of the ICH M11 Protocol standard, Analyses of Demographics and Other Baseline Variables."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4 Analyses Associated with the Primary Objective(s)",
                    "definition": "Section 10.4 of the ICH M11 Protocol standard, Analyses Associated with the Primary Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.1 Statistical Method of Analysis",
                    "definition": "Section 10.4.1 of the ICH M11 Protocol standard, Statistical Method of Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.2 Handling of Data in Relation to Primary Estimand(s)",
                    "definition": "Section 10.4.2 of the ICH M11 Protocol standard, Handling of Data in Relation to Primary Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.3 Handling of Missing Data",
                    "definition": "Section 10.4.3 of the ICH M11 Protocol standard, Handling of Missing Data."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.4 Sensitivity Analysis",
                    "definition": "Section 10.4.4 of the ICH M11 Protocol standard, Sensitivity Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.5 Supplementary Analysis",
                    "definition": "Section 10.4.5 of the ICH M11 Protocol standard, Supplementary Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5 Analysis Associated with the Secondary Objective(s)",
                    "definition": "Section 10.5 of the ICH M11 Protocol standard, Analysis Associated with the Secondary Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.1 Statistical Method of Analysis",
                    "definition": "Section 10.5.1 of the ICH M11 Protocol standard, Statistical Method of Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.2 Handling of Data in Relation to Secondary Estimand(s)",
                    "definition": "Section 10.5.2 of the ICH M11 Protocol standard, Handling of Data in Relation to Secondary Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.3 Handling of Missing Data in Relation to Secondary Estimand(s)",
                    "definition": "Section 10.5.3 of the ICH M11 Protocol standard, Handling of Missing Data in Relation to Secondary Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.4 Sensitivity Analyses",
                    "definition": "Section 10.5.4 of the ICH M11 Protocol standard, Sensitivity Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.5 Supplementary Analyses",
                    "definition": "Section 10.5.5 of the ICH M11 Protocol standard, Supplementary Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.6 Analysis Associated with the Exploratory Objective(s)",
                    "definition": "Section 10.6 of the ICH M11 Protocol standard, Analysis Associated with the Exploratory Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.7 Safety Analyses",
                    "definition": "Section 10.7 of the ICH M11 Protocol standard, Safety Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.8 Other Analyses",
                    "definition": "Section 10.8 of the ICH M11 Protocol standard, Other Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.9 Interim Analyses",
                    "definition": "Section 10.9 of the ICH M11 Protocol standard, Interim Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.10 Multiplicity Adjustments",
                    "definition": "Section 10.1 of the ICH M11 Protocol standard, Multiplicity Adjustments."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.11 Sample Size Determination",
                    "definition": "Section 10.11 of the ICH M11 Protocol standard, Sample Size Determination."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS",
                    "definition": "Section 11 of the ICH M11 Protocol standard, TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.1 Regulatory and Ethical Considerations",
                    "definition": "Section 11.1 of the ICH M11 Protocol standard, Regulatory and Ethical Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.2 Trial Oversight",
                    "definition": "Section 11.2 of the ICH M11 Protocol standard, Trial Oversight."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.2.1 Investigator Responsibilities",
                    "definition": "Section 11.2.1 of the ICH M11 Protocol standard, Investigator Responsibilities."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.2.2 Sponsor Responsibilities",
                    "definition": "Section 11.2.2 of the ICH M11 Protocol standard, Sponsor Responsibilities."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.3 Informed Consent Process",
                    "definition": "Section 11.3 of the ICH M11 Protocol standard, Informed Consent Process."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.3.1 Informed Consent for Rescreening",
                    "definition": "Section 11.3.1 of the ICH M11 Protocol standard, Informed Consent for Rescreening."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research",
                    "definition": "Section 11.3.2 of the ICH M11 Protocol standard, Informed Consent for Use of Remaining Samples in Exploratory Research."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.4 Committees",
                    "definition": "Section 11.4 of the ICH M11 Protocol standard, Committees."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.5 Insurance and Indemnity",
                    "definition": "Section 11.5 of the ICH M11 Protocol standard, Insurance and Indemnity."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.6 Risk Management",
                    "definition": "Section 11.5 of the ICH M11 Protocol standard, Risk Management."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.7 Data Governance",
                    "definition": "Section 11.7 of the ICH M11 Protocol standard, Data Governance."
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11. Source Data",
                    "definition": "Section 11. of the ICH M11 Protocol standard, Source Data."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": " Protocol Deviations",
                    "definition": "Section  of the ICH M11 Protocol standard, Protocol Deviations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": " Early Site Closure",
                    "definition": "Section 11.1 of the ICH M11 Protocol standard, Early Site Closure."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12 APPENDIX: SUPPORTING DETAILS",
                    "definition": "Section 12 of the ICH M11 Protocol standard, APPENDIX: SUPPORTING DETAILS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12.1 Clinical Laboratory Tests",
                    "definition": "Section 12.1 of the ICH M11 Protocol standard, Clinical Laboratory Tests."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12.2 Country/Region-Specific Differences",
                    "definition": "Section 12.2 of the ICH M11 Protocol standard, Country/Region-Specific Differences."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12.3 Prior Protocol Amendment(s)",
                    "definition": "Section 12.3 of the ICH M11 Protocol standard, Prior Protocol Amendment(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS",
                    "definition": "Section 13 of the ICH M11 Protocol standard, APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "14 APPENDIX: REFERENCES",
                    "definition": "Section 14 of the ICH M11 Protocol standard, APPENDIX: REFERENCES."
                }
            ]
        },
        "Table of Contents": {
            "name": "Table of Contents",
            "data_type": "Word Generated Table of Contents",
            "definition": "N/A",
            "guidance": "N/A",
            "conformance": "Generated",
            "cardinality": "N/A",
            "relationship": "Table of Contents",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: N/A\nConcept: N/A",
            "repeating": "No",
            "ct": []
        },
        "Intervention Model": {
            "name": "Intervention Model",
            "data_type": "Valid Value",
            "definition": "C98746\nFor review purpose, see definition of the controlled terminology below\nThe overall design configuration for assigning intervention to participants.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one; One to Heading On toProtocol Identifier",
            "relationship": "1.1.2",
            "value": "Single group (C82640), parallel group (C82639), cross-over (C82637), factorial(C8263), sequential (C142568), other(C17649)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title; Protocol Identifier\nConcept: C98746",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C99076",
                    "preferred_term": "INTMODEL",
                    "definition": "A terminology codelist relevant to the trial design developed to compare treatment groups."
                },
                {
                    "ncit_code": "C82637",
                    "preferred_term": "Cross-over",
                    "definition": "Participants receive one of two or more alternative intervention(s) during the initial epoch of the study and receive other intervention(s) during the subsequent epoch(s) of the study."
                },
                {
                    "ncit_code": "C82638",
                    "preferred_term": "Factorial",
                    "definition": "Two or more interventions, each alone or in combination, are evaluated in parallel against a control group. This study design allows for the comparison of active drug to placebo, presence of drug-drug interactions, and comparison of active drugs against each other."
                },
                {
                    "ncit_code": "C82639",
                    "preferred_term": "Parallel Group",
                    "definition": "Participants are assigned to one of two or more treatment groups in parallel for the duration of the study."
                },
                {
                    "ncit_code": "C142568",
                    "preferred_term": "Sequential",
                    "definition": "Groups of participants are assigned to receive interventions based on prior milestones being reached in the study."
                },
                {
                    "ncit_code": "C82640",
                    "preferred_term": "Single Group",
                    "definition": "All trial participants are assigned to a single treatment group for the duration of the study."
                },
                {
                    "ncit_code": "C17649",
                    "preferred_term": "Other",
                    "definition": "Different than the one(s) previously specified or mentioned."
                }
            ]
        },
        "Population Type": {
            "name": "Population Type",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA characterisation or classification of the trial population.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one; One to Heading; One to Protocol Identifier",
            "relationship": "1.1.2",
            "value": "With Disease (CNEW); Without Disease (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title; Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Population Type Response",
                    "definition": "A terminology value set relevant to the study population type responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "With Disease",
                    "definition": "An indication that the individual or group of individuals has been diagnosed with the disease of interest or under study."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Without Disease",
                    "definition": "An indication that the individual or group of individuals has not been diagnosed with the disease of interest or under study."
                }
            ]
        },
        "Control Type ": {
            "name": "Control Type ",
            "data_type": "Valid Value",
            "definition": "C49647\nFor review purpose, see definition of the controlled terminology below\nA characterisation or classification of the comparator against which the study intervention is evaluated.",
            "guidance": "Control method (for example, placebo, active comparator, low dose, historical, standard of care, sham procedure, or none [uncontrolled])",
            "conformance": "Required",
            "cardinality": "One to one; One to Heading; One to Protocol Identifier",
            "relationship": "1.1.2",
            "value": "Placebo (C49648), active comparator(C49649), Dose Response(C120841); Different Dose or Regimen (CNEW), External (CNEW), sham procedure(C184727), or No Control(C)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title; Protocol Identifier\nConcept: C49647",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66785",
                    "preferred_term": "TCNTRL",
                    "definition": "A terminology codelist relevant to a comparator against which the study treatment is evaluated."
                },
                {
                    "ncit_code": "C49649",
                    "preferred_term": "Active Comparator",
                    "definition": "A type of control, which has a demonstrated effect, administered as a comparator to subjects in a clinical trial."
                },
                {
                    "ncit_code": "C120841",
                    "preferred_term": "Dose Response",
                    "definition": "A type of control using different doses or regimens of the same treatment across the treatment arms."
                },
                {
                    "ncit_code": "C28280",
                    "preferred_term": "No Control",
                    "definition": "A clinical study that lacks a comparison (i.e., a control) group."
                },
                {
                    "ncit_code": "C49648",
                    "preferred_term": "Placebo",
                    "definition": "An inactive, identical-appearing drug or treatment that does not contain the test product."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Different Dose or Regimen",
                    "definition": "A type of control that comprises a different dose or dosage regimen in comparison to the investigational intervention dose or dosage regimen. "
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "External",
                    "definition": "The use of external control data as a control arm for those studies where ethical concerns and/or underserved disease indications may make it difficult to enroll subjects/participants."
                },
                {
                    "ncit_code": "C184727",
                    "preferred_term": "Sham Procedure",
                    "definition": "A type of negative control in which a procedure is performed that mimics the procedure under study but does not include investigational processes or components."
                }
            ]
        },
        "Nonproprietary name or INN or Enter Not applicable": {
            "name": "Nonproprietary name or INN or Enter Not applicable",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the comparator against which the study intervention is evaluated.",
            "guidance": "",
            "conformance": "Conditional: if there is a nonproprietary name or INN",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "[Nonproprietary name] or [INN] or <Enter \u201cN/A\u201d>",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title; Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Nonproprietary name ": {
            "name": "Nonproprietary name ",
            "data_type": "Valid Value ",
            "definition": "C97054\nFor review purpose, see definition of the controlled terminology below\nDrug name that is not protected by a trademark, usually descriptive of its chemical structure. (ICH E2B)",
            "guidance": "",
            "conformance": "Conditional: if there is a Nonproprietary name",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "Use for example WHO INN, USAN, JAN, XEVMPD",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title; Control Description; Protocol Identifier\nConcept: C97054",
            "repeating": "Yes, repeatable for each nonproprietary name",
            "ct": []
        },
        "or INN or ": {
            "name": "or INN or ",
            "data_type": "Valid Value",
            "definition": "C142585\nFor review purpose, see definition of the controlled terminology below\nA unique name that is globally recognised and public property, which identifies pharmaceutical substances or active pharmaceutical ingredients. (After WHO)",
            "guidance": "",
            "conformance": "Conditional:  if there is an INN",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "or use for example WHO INN, USAN, JAN, XEVMPD",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title; Control Description; Protocol Identifier\nConcept: C142585",
            "repeating": "Yes, repeatable for each INN",
            "ct": []
        },
        "Not applicable": {
            "name": "Not applicable",
            "data_type": "Text",
            "definition": "Verbatim Text",
            "guidance": "",
            "conformance": "Conditional: if there is no nonproprietary name and INN",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "N/A",
            "business_rules": "Value Allowed: Yes, cannot have not applicable if Nonproprietary or INN are completed\nRelationship: Row title; Control Description; Protocol Identifier\nConcept: Verbatim Text",
            "repeating": "No",
            "ct": []
        },
        "units of age": {
            "name": "units of age",
            "data_type": "Valid Value",
            "definition": "C50400\nFor review purpose, see definition of the controlled terminology below\nThose units of time that are routinely used to express the age of a person.",
            "guidance": "Population age range - For trials in which multiple age ranges may be eligible (for example, a younger cohort and an older cohort), indicate the minimum and maximum ages for the trial overall, with an additional comment for any excluded age ranges.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "hour (C25529), day (C25301), weeks (C29844), months (C29846), years (C29848)",
            "business_rules": "Value Allowed: Yes\nRelationship: Population Age; Maximum, Numeric Maximum\nConcept: C50400",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Units of Time",
                    "definition": "A terminology value set relevant to units of time within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25301",
                    "preferred_term": "DAYS",
                    "definition": "A unit of measurement of time equal to 24 hours."
                },
                {
                    "ncit_code": "C25529",
                    "preferred_term": "HOURS",
                    "definition": "A unit of measurement of time equal to 60 minutes."
                },
                {
                    "ncit_code": "C29846",
                    "preferred_term": "MONTHS",
                    "definition": "One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks."
                },
                {
                    "ncit_code": "C29844",
                    "preferred_term": "WEEKS",
                    "definition": "Any period of seven consecutive days."
                },
                {
                    "ncit_code": "C29848",
                    "preferred_term": "YEARS",
                    "definition": "The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period."
                }
            ]
        },
        " ": {
            "name": " ",
            "data_type": "Number",
            "definition": "C49694\nFor review purpose, see definition of the controlled terminology below\nThe anticipated maximum age of the participants to be entered in a clinical trial",
            "guidance": "Population age range - For trials in which multiple age ranges may be eligible (for example, a younger cohort and an older cohort), indicate the minimum and maximum ages for the trial overall, with an additional comment for any excluded age ranges.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Integer",
            "business_rules": "Value Allowed: Yes\nRelationship: population age, Maximum Age; Maximum unit of age\nConcept:C49694",
            "repeating": "No",
            "ct": []
        },
        "Intervention Assignment Method": {
            "name": "Intervention Assignment Method",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe process used to assign trial participants to a trial intervention or trial arm.",
            "guidance": "\nIntervention assignment method - Do NOT state block size.",
            "conformance": "Required",
            "cardinality": "One to one: One to Protocol Identifier",
            "relationship": "1.1.2",
            "value": "Randomisation (C25196), Stratification (C25689), Stratified Randomisation (CNEW), Other (C17649) or Not Applicable (C48660)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title identifier; Protocol Identifiers\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Intervention Assignment Method Response",
                    "definition": "A terminology value set relevant to the trial intervention assignment method responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25196",
                    "preferred_term": "Randomisation",
                    "definition": "The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group."
                },
                {
                    "ncit_code": "C25689",
                    "preferred_term": "Stratification",
                    "definition": "Grouping defined by important prognostic factors measured at baseline."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Stratified Randomisation",
                    "definition": "The process of grouping trial participants into strata according to important prognostic factors and then assigning participants within each stratum to different treatment or control groups using an element of chance and in order to reduce bias."
                }
            ]
        },
        "Site Distribution": {
            "name": "Site Distribution",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the occurrence applies to a single or multiple trial sites.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "single-centre (CNEW), multi-centre(CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title heading; Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Site Distribution Response",
                    "definition": "A terminology value set relevant to the trial site distribution responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Single-Centre",
                    "definition": "A clinical study that is conducted at a single study site."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Multicentre",
                    "definition": "A clinical trial conducted according to a single protocol but at more than one site, and therefore, carried out by more than one investigator."
                }
            ]
        },
        "Blinded roles": {
            "name": "Blinded roles",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn identifying designation assigned to a blinded individual within a clinical trial that corresponds with their function",
            "guidance": "\u201cNot applicable (No blinding)\u201d indicates an open label trial.",
            "conformance": "Required",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "Participant (C142710), Care Provider (C17445), Investigator (C25936), Outcomes Assessor (CNEW), Sponsor (C70793) Not Applicable (C48660)",
            "business_rules": "Value Allowed: Yes, Multiple roles can be selected\nRelationship: Blinded Roles\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Blinding Role",
                    "definition": "A terminology value set relevant to the trial blinding roles within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C142710",
                    "preferred_term": "Participant",
                    "definition": " A member of the clinical study population from whom data are being collected."
                },
                {
                    "ncit_code": "C17445",
                    "preferred_term": "Care Provider",
                    "definition": "The primary person in charge of the care of a patient, usually a family member or a designated health care professional."
                },
                {
                    "ncit_code": "C25936",
                    "preferred_term": "Investigator",
                    "definition": "A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at the trial site, the investigator is the responsible leader of the team and may be called the principal investigator."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Outcomes Assessor",
                    "definition": "The individual who evaluates the outcome(s) of interest."
                },
                {
                    "ncit_code": "C70793",
                    "preferred_term": "Sponsor",
                    "definition": "An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study."
                },
                {
                    "ncit_code": "C48660",
                    "preferred_term": "Not Applicable",
                    "definition": "Determination of a value is not relevant in the current context."
                }
            ]
        },
        "TargetMaximum": {
            "name": "TargetMaximum",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA characterisation or classification of the trial participant numbers as to whether the numbers reflect a target or maximum.",
            "guidance": "State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "A (choose Target/Maximum) of",
            "business_rules": "Value Allowed: Yes\nRelationship:  \nConcept: CNEW",
            "repeating": "No ",
            "ct": []
        },
        "randomly assigned to trial intervention enrolled": {
            "name": "randomly assigned to trial intervention enrolled",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe target or maximum number of participants who have been randomly assigned to the trial intervention or enrolled in the trial.",
            "guidance": "State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "randomly assigned to trial intervention/enrolled",
            "business_rules": "Value Allowed: \nRelationship: \nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Trialspecific Intervention Risks and Mitigations": {
            "name": "Trialspecific Intervention Risks and Mitigations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with the trial interventions and mitigation strategies to be employed within the trial.",
            "guidance": "Trial Intervention \u2013 Describe risks related to trial-specific treatments and interventions. For the protocol, focus on the relevant key risks for THIS trial. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "2.2.",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2. Risk Summary and Mitigation Strategy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Trialspecific Procedure Risks and Mitigations": {
            "name": "Trialspecific Procedure Risks and Mitigations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with the trial procedures and mitigation strategies to be employed within the trial.",
            "guidance": "Trial Procedures \u2013 risks associated with the design (, placebo arm) and procedures specific to  trial (, biopsies), and any measures to control or mitigate the risks. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section. This is not intended to be an exhaustive list of all possible risks associated with trial procedures but should focus on the unique risks inherent in the design or less common or high-risk procedures. As above, provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "2.2. ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2. Risk Summary and Mitigation Strategy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Trialspecific Other Risks and Mitigations": {
            "name": "Trialspecific Other Risks and Mitigations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with other trial-related agents and mitigation strategies to be employed within the trial.",
            "guidance": "Other \u2013 Consider risks associated with other items (, challenge agents, imaging agents, medical devices). This could include discussion of risk mitigation for special populations, if not described elsewhere. Insert a line for each, as needed.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "2.2.",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2. Risk Summary and Mitigation Strategy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        " Table of Estimand Characteristics including Endpoint at a minimum": {
            "name": " Table of Estimand Characteristics including Endpoint at a minimum",
            "data_type": "Text",
            "definition": "N/A",
            "guidance": "N/A",
            "conformance": " ",
            "cardinality": "One to one",
            "relationship": "3.1.X",
            "value": "Estimand Characteristics",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: Heading",
            "repeating": "\n\n",
            "ct": []
        },
        "PopulationLevel Summary": {
            "name": "PopulationLevel Summary",
            "data_type": "Text",
            "definition": "C188853\nFor review purpose, see definition of the controlled terminology below\n A synopsis of the clinical endpoint of interest within the analysis target study population.",
            "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status)",
            "conformance": "Conditional: If there is a ",
            "cardinality": "One to Row Heading, One Exploratory Objective Table, Project Identifier ",
            "relationship": "3.3.X ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand\nConcept: C188857",
            "repeating": "\n",
            "ct": []
        },
        "Intercurrent Event Strategy": {
            "name": "Intercurrent Event Strategy",
            "data_type": "Text",
            "definition": "C188857\nFor review purpose, see definition of the controlled terminology below\nA textual description of the planned strategy to address intercurrent events.",
            "guidance": "Description of the strategy to address the intercurrent event (e.g. a treatment policy strategy); cross-reference the justification in Section 4. If there is >1 intercurrent event for an objective, add additional intercurrent event rows",
            "conformance": "",
            "cardinality": "One to one ",
            "relationship": "3.3.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading Strategy, Description\nConcept: C188857",
            "repeating": "Yes, repeatable for each intercurrent event",
            "ct": []
        },
        "If a Secondary Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum": {
            "name": "If a Secondary Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum",
            "data_type": "Text",
            "definition": "N/A",
            "guidance": "{If a Secondary Objective has been entered: <Enter Table of Estimand Characteristics>} including Endpoint at a minimum}",
            "conformance": "Conditional: either Enter Table of Estimand Characteristics or details of the characteristics relevant to objective",
            "cardinality": "One to many rows",
            "relationship": "3.2.X",
            "value": "Estimand Characteristics",
            "business_rules": "Value Allowed: No\nRelationship: 3 3.2 Secondary Objective(s) and associated Estimand(s)\nConcept: Heading",
            "repeating": "\n\n",
            "ct": []
        },
        "If an Exploratory Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum": {
            "name": "If an Exploratory Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum",
            "data_type": "Text",
            "definition": "N/A",
            "guidance": "{If an Exploratory Objective has been entered: <Table of Estimand Characteristics> including Endpoint at a minimum}",
            "conformance": "Conditional: either Enter Table of Estimand Characteristics or details of the characteristics relevant to objective",
            "cardinality": "One to many",
            "relationship": "3.3.X",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.3.3 Exploratory Objective(s) and associated Estimand(s);Table column Heading; Description, Population, Treatment, Endpoint, Population-Level, Intercurrent Event (1\u2026n)\nConcept: Heading",
            "repeating": "\n",
            "ct": []
        },
        "Description of Trial ": {
            "name": "Description of Trial ",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the trial duration.",
            "guidance": "Describe the overall trial design and intervention model (e.g., single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (e.g., placebo, active comparator, low dose, external, standard of care, sham procedure, or none [uncontrolled]). If there are any key aspects of the investigational trial intervention that inform the selection of the intervention model, this should be described.\nIf applicable, indicate other design characteristics (e.g., superiority, noninferiority, dose escalation, or equivalence).\nIf the trial will have an adaptive or novel design (e.g., the trial will be conducted under a master protocol), provide a summary of these design aspects.\nIf applicable, describe within-trial transition rules, e.g., transitions involving cohorts or trial parts. Dose escalation or dose-ranging details should also be described.",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\n\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Description of Level of Blinding": {
            "name": "Description of Level of Blinding",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the level of awareness of the study participants and/or personnel to the respective intervention(s) or assessments being observed, received or administered",
            "guidance": "N/A",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "4.1 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\n\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Rationale for Trial Intervention Model": {
            "name": "Rationale for Trial Intervention Model",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for why the intervention model was chosen for the trial.",
            "guidance": "Provide a rationale for the trial intervention model described in Section 4.1 Description of Trial Design with a cross-reference to Section 6.2 Rationale for Investigational Intervention Dose and Regimen. Rationale for choice of comparator, if applicable, should be described separately in Section 4.2.5 Rationale for Control Type. A rationale for the choice of trial population should be described separately in Section 5.1 Description of Trial Population and Rationale.\n",
            "conformance": "Conditional: when  is not used",
            "cardinality": "One to one",
            "relationship": "4.2.",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.Rational for Intervention Model\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Prospective approval of protocol deviations to recruitment and enrollment criteria also known as protocol waivers or exemptions is not permitted": {
            "name": "Prospective approval of protocol deviations to recruitment and enrollment criteria also known as protocol waivers or exemptions is not permitted",
            "data_type": "Text",
            "definition": "Universal Text",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.1",
            "value": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.",
            "business_rules": "Value Allowed: No\nRelationship: 5.1 Description of Trial Population and Rationale\n\n\nConcept: Universal text",
            "repeating": "No",
            "ct": []
        },
        "To be eligible to participate in this trial an individual must meet all the following criteria": {
            "name": "To be eligible to participate in this trial an individual must meet all the following criteria",
            "data_type": "Text",
            "definition": "Universal text",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to ",
            "relationship": "5.2",
            "value": "To be eligible to participate in this trial, an individual must meet all the following criteria:",
            "business_rules": "Value Allowed: No\nRelationship: 5.2 Inclusion Criteria\nConcept: niversal text",
            "repeating": "No",
            "ct": []
        },
        "Inclusion Criterion": {
            "name": "Inclusion Criterion",
            "data_type": "Text",
            "definition": "C25532 \nFor review purpose, see definition of the controlled terminology below\nThe criteria in a protocol that prospective subjects must meet to be eligible for participation in a study.",
            "guidance": "Add criteria as needed. sequentially",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: to Number # 5.2 Inclusion Criteria\nConcept: C25532",
            "repeating": "umber consecutively, repeat for each inclusion criteria, if deleted do not replace, do not duplicate",
            "ct": []
        },
        "An individual who meets any of the following criteria will be excluded from participation in this trial": {
            "name": "An individual who meets any of the following criteria will be excluded from participation in this trial",
            "data_type": "Text",
            "definition": "Universal text",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.3",
            "value": "An individual who meets any of the following criteria will be excluded from participation in this trial:",
            "business_rules": "Value Allowed: No\nRelationship: 5.3 Exclusion Criteria, 5 TRIAL POPULATION and Table of Contents\nConceptniversal text",
            "repeating": "No",
            "ct": []
        },
        "Exclusion Criterion": {
            "name": "Exclusion Criterion",
            "data_type": "Text",
            "definition": "C25370\nFor review purpose, see definition of the controlled terminology below\nList of characteristics in a protocol, any one of which excludes a potential subject from participation in a study. (CDISC glossary)",
            "guidance": "Add criteria as needed. the criteria sequentially",
            "conformance": "Required",
            "cardinality": "One to many",
            "relationship": "5.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: to Number #, 5.3 Exclusion Criteria\nConcept: C25370",
            "repeating": "Yes, repeatable for each exclusion criterion, if deleted do not replace, do not duplicate",
            "ct": []
        },
        "Definitions Related to Childbearing Potential": {
            "name": "Definitions Related to Childbearing Potential",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of participants of childbearing potential and non-childbearing potential within the context of a trial, or state not applicable.",
            "guidance": "Specify the definitions of:\narticipant of childbearing potential\n\narticipant of nonchildbearing potential",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.4.1 Definitions Related to Childbearing Potential\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Contraception Requirements": {
            "name": "Contraception Requirements",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the requirements for the prevention of conception or impregnation by the use of devices or drugs or surgery within a context of a trial l, or state not applicable. ",
            "guidance": "Specify the: \nontraceptive methods required \nuration of use",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.4.2 Contraception requirements\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Caffeine Alcohol Tobacco and Other Restrictions": {
            "name": "Caffeine Alcohol Tobacco and Other Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the restrictions related to participant intake of caffeine, alcohol, tobacco, and other habit-forming substances during the trial.",
            "guidance": "If applicable, describe any restrictions on the intake of caffeine, alcohol, tobacco, or other restrictions. \n",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.2.2 Caffeine, Alcohol, Tobacco, and Other Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Description of the overview of trial interventions or a heading for the optional table below": {
            "name": "Description of the overview of trial interventions or a heading for the optional table below",
            "data_type": "Text",
            "definition": "",
            "guidance": "Trial interventions are all pre-specified, investigational and non-investigational medicinal products, medical devices or other interventions intended for the participants during the trial. The investigational trial intervention is the product used in the trial as part of trial objectives. Description of investigational trial intervention is provided in Section 6.1. Other trial interventions that are not part of trial objectives (not an investigational role in this trial) are described in Section 6.9 Description of Non-investigational trial interventions. \nAny regional requirements should be noted in the appropriate subsections. \nProvide an overview of investigational and non-investigational trial interventions. Classify the trial intervention as IMP, NIMP/AxMP designations based on study design and local legislation. Consider the optional table below",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "6",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: 6 TRIAL INTERVENTION AND CONCOMITANT THERAPY\nConcept: ",
            "repeating": "No",
            "ct": []
        },
        "Arm Type": {
            "name": "Arm Type",
            "data_type": "Valid Value",
            "definition": "C172457\nFor review purpose, see definition of the controlled terminology below\nA characterization or classification of the study arm.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each arm name",
            "relationship": "6",
            "value": "Experimental Arm(C174266), Active Comparator Arm(C174267), Placebo Comparator Arm (C174268, Sham Comparator Arm (C174269), No Intervention Arm (C174270), Control Arm(C174226)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and arm type\n\nConcept: C172457",
            "repeating": "Yes, repeatable for each arm name",
            "ct": [
                {
                    "ncit_code": "C174222",
                    "preferred_term": "Study Arm Type Value Set Terminology",
                    "definition": "The terminology relevant to the identification of the kind of arm."
                },
                {
                    "ncit_code": "C174267",
                    "preferred_term": "Active Comparator Arm",
                    "definition": "An arm describing the active comparator."
                },
                {
                    "ncit_code": "C174226",
                    "preferred_term": "Control Arm",
                    "definition": "An arm describing the intervention or treatment plan for a group of participants in the study receiving a control. The control may comprise a non-investigational product (active control) or regimen, placebo, or no treatment."
                },
                {
                    "ncit_code": "C174266",
                    "preferred_term": "Experimental Arm",
                    "definition": "An arm describing the intervention or treatment plan for a group of participants in the study receiving test product(s)."
                },
                {
                    "ncit_code": "C174270",
                    "preferred_term": "No Intervention Arm",
                    "definition": "A study arm without an intervention or treatment."
                },
                {
                    "ncit_code": "C174268",
                    "preferred_term": "Placebo Comparator Arm",
                    "definition": "An arm describing the placebo comparator."
                },
                {
                    "ncit_code": "C174269",
                    "preferred_term": "Sham Comparator Arm",
                    "definition": "An arm describing the sham comparator."
                }
            ]
        },
        "Intervention Type": {
            "name": "Intervention Type",
            "data_type": "Valid Value ",
            "definition": "C98747\nFor review purpose, see definition of the controlled terminology below\nThe kind of product or procedure studied in a trial.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention name",
            "relationship": "6",
            "value": "Drug (C1909), Device (C16830), Biologic (C307), Vaccine (C923), Non-Surgical Procedure (CNEW), Surgery (C15329), Radiation (C15313), Behavioral (C15184), Genetic (C15238), Dietary Supplement (C1505), Combination Product (C54696), Diagnostic Test (C18020)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and Intervention name, \nConcept: C98747",
            "repeating": "Yes, repeatable for each arm name",
            "ct": [
                {
                    "ncit_code": "C99078",
                    "preferred_term": "INTTYPE",
                    "definition": "A terminology codelist relevant to the kind of product or procedure studied in a trial."
                },
                {
                    "ncit_code": "C15184",
                    "preferred_term": "Behavioral",
                    "definition": "A technique used to change the behavior of a subject (e.g., psychotherapy, lifestyle counseling, or hypnosis)."
                },
                {
                    "ncit_code": "C307",
                    "preferred_term": "Biologic",
                    "definition": "A product of biological origin applicable to the prevention, treatment, or cure of a disease or condition, for example: virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product."
                },
                {
                    "ncit_code": "C923",
                    "preferred_term": "Vaccine",
                    "definition": "A medicinal product inducing immunity against disease, most often to prevent occurrence of a disease, (e.g., a preventative vaccine against infectious disease), but also to treat a disease, (e.g., a therapeutic vaccine against cancer)."
                },
                {
                    "ncit_code": "C54696",
                    "preferred_term": "Combination Product",
                    "definition": "A product composed of two or more different types of medical products (i.e., a combination of a drug, device, and/or biological product with one another and are referred to as \"constituent parts\" of the combination product)."
                },
                {
                    "ncit_code": "C16830",
                    "preferred_term": "Device",
                    "definition": "Any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, intended by the manufacturer to be used, alone or in combination for, one or more specific medical purpose(s)."
                },
                {
                    "ncit_code": "C1505",
                    "preferred_term": "Dietary Supplement",
                    "definition": "Preparations containing ingredient(s) intended to supplement the diet."
                },
                {
                    "ncit_code": "C1909",
                    "preferred_term": "Drug",
                    "definition": "An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient."
                },
                {
                    "ncit_code": "C15238",
                    "preferred_term": "Genetic",
                    "definition": "Introduction of genetic material into cells in order to correct or treat an inherited or acquired disease."
                },
                {
                    "ncit_code": "C15329",
                    "preferred_term": "Surgery",
                    "definition": "A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Non-Surgical Procedure",
                    "definition": "A medical procedure that produces an effect, or that is intended to alter the course of a disease in a patient or population, which is not considered a surgical procedure."
                },
                {
                    "ncit_code": "C15313",
                    "preferred_term": "Radiation",
                    "definition": "Use of targeted or whole body radiation to treat a disease."
                },
                {
                    "ncit_code": "C18020",
                    "preferred_term": "Diagnostic Test",
                    "definition": "Any procedure or test to diagnose a disease or disorder."
                }
            ]
        },
        "Pharmaceutical Dose Formulation": {
            "name": "Pharmaceutical Dose Formulation",
            "data_type": "Valid Value",
            "definition": "C42636\nFor review purpose, see definition of the controlled terminology below\nPhysical characteristics of a drug product, (e.g. tablet, capsule, or solution) that contains a drug substance, generally-but not necessarily-in association with one or more other ingredients",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each arm name, arm type and intervention combination",
            "relationship": "6",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and dosage formulation\n\nConcept: C42636",
            "repeating": "Yes, repeatable for each intervention and dosage formulation",
            "ct": []
        },
        "Dosage Strengths": {
            "name": "Dosage Strengths",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe strength of a drug product, which indicates the amount of each active ingredient in a given dosage form, measured in units of volume or concentration.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each dosage formulation ",
            "relationship": "Trial Intervention and Concomitant Therapy",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and dose strength, 6 Trial Intervention and Concomitant Therapy\nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention and formulation per arm name and arm type",
            "ct": []
        },
        "Dosage Levels": {
            "name": "Dosage Levels",
            "data_type": "Text",
            "definition": "C94394\nFor review purpose, see definition of the controlled terminology below\nSpecified quantity of a medicine, to be taken at one time or at stated intervals. [ISO 11615:2012 Health Informatics]",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention and dosage formulation",
            "relationship": "6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and dose level\n\nConcept: C94394",
            "repeating": "Yes, repeatable for each intervention, dose formulation, dosage strength and dosage level per arm ",
            "ct": []
        },
        "RegimenTreatment PeriodVaccination regimen": {
            "name": "RegimenTreatment PeriodVaccination regimen",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the schedule and periodicity of a treatment or vaccination regimen.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention, dose formulation, dosage strength per arm",
            "relationship": "6",
            "value": "Regimen/Treatment Period",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and regimen/treatment period/vaccine regimen, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each arm name",
            "ct": []
        },
        "Use": {
            "name": "Use",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe reason or intention for the use of the trial intervention within the trial arm.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention",
            "relationship": "6",
            "value": "Experimental Intervention(C41161), Placebo(C753), Rescue Medicine(C165835), Background treatment(C165822), Challenge Agent(C158128), Diagnostic(C18020), Additional Required treatment (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and use, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention per arm",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Intervention Use Response",
                    "definition": "A terminology value set relevant to the intervention use responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C41161",
                    "preferred_term": "Experimental Intervention",
                    "definition": "The drug, device, therapy, procedure, or process under investigation in a clinical study that is believed to have an effect on outcomes of interest in a study (e.g., health-related quality of life, efficacy, safety, pharmacoeconomics"
                },
                {
                    "ncit_code": "C753",
                    "preferred_term": "Placebo",
                    "definition": "A pharmaceutical preparation that does not contain the investigational agent and is generally prepared to be physically indistinguishable from the preparation containing the investigational product."
                },
                {
                    "ncit_code": "C165835",
                    "preferred_term": "Rescue Medicine",
                    "definition": "Medicinal products identified in the protocol as those that may be administered to subjects when the efficacy of the investigational medicinal product (IMP) is not satisfactory, the effect of the IMP is too great and is likely to cause a hazard to the patient, or to manage an emergency situation."
                },
                {
                    "ncit_code": "C165822",
                    "preferred_term": "Background Treatment",
                    "definition": "Medicinal products that are administered to each clinical trial subject, regardless of randomization group, a) to treat the indication which is the object of the study, or b) required in the protocol as part of standard care for a condition that is not the indication under investigation, and is relevant for the clinical trial design."
                },
                {
                    "ncit_code": "C158128",
                    "preferred_term": "Challenge Agent",
                    "definition": "A non-investigational medicinal product (NIMP) given to trial subjects to produce a physiological response that is necessary before the pharmacological action of the investigational medicinal product can be assessed."
                },
                {
                    "ncit_code": "C18020",
                    "preferred_term": "Diagnostic",
                    "definition": "Any procedure or test to diagnose a disease or disorder."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Additional Required Treatment",
                    "definition": "A medicinal product that must be administered along with the experimental treatment (e.g., drug studies wherein opioid blockers are administered to prevent overdose)."
                }
            ]
        },
        "IMPNIMP": {
            "name": "IMPNIMP",
            "data_type": "Valid value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the investigational intervention is an investigational medicinal product or an auxiliary medicinal product.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention",
            "relationship": "6",
            "value": "IMP(CNEW), NIMP(C156473)",
            "business_rules": "Value Allowed: Yes\nRelationship: One per each intervention \nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention per arm",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Investigational Medicinal Product Indicator Response",
                    "definition": "A terminology value set relevant to the investigational medicinal product indicator responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "IMP",
                    "definition": "A medicinal product which is being tested or used as a reference, including as a placebo, in a clinical trial."
                },
                {
                    "ncit_code": "C156473",
                    "preferred_term": "NIMP (AxMP)",
                    "definition": "A medicinal product that is related to the specific needs of the clinical trial as described in the protocol, but not as an investigational medicinal product."
                }
            ]
        },
        "Sourcing": {
            "name": "Sourcing",
            "data_type": "Valid Value",
            "definition": "CNEW\nCNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the investigational intervention is sourced from a local or central vendor.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to many",
            "relationship": "6",
            "value": "Centrally Sourced (CNEW); Locally Sourced (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: One per each Intervention\nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention per arm name",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Investigational Intervention Sourcing Response",
                    "definition": "A terminology value set relevant to the investigational intervention source responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Centrally Sourced",
                    "definition": "An indication that the entity is obtained from a central vendor."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Locally Sourced",
                    "definition": "An indication that the entity is obtained from a local vendor."
                }
            ]
        },
        "Additional Text if Needed": {
            "name": "Additional Text if Needed",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nExtra or further descriptive text that is optionally added as needed.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "6.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.1 Description of Investigational Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Preparation of Investigational Trial Intervention": {
            "name": "Preparation of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "C176274\nFor review purpose, see definition of the controlled terminology below\nThe way in which the investigational trial intervention is prepared for use or administration to the study participant.",
            "guidance": "Describe any preparation of the investigational trial intervention, and when necessary, by whom. When applicable, describe the maximum hold time once thawed/mixed before administration. Include thawing, diluting, mixing, and reconstitution/preparation instructions. For drug/device combination products, include any relevant assembly or use instructions and reference the package insert that is provided separately.\u00a0\nIf the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents.\u00a0\n",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.6.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.6.1 Preparation of Investigational Trial Intervention\nConcept: C176274",
            "repeating": "No",
            "ct": []
        },
        "Blinding": {
            "name": "Blinding",
            "data_type": "Text",
            "definition": "C189349\nFor review purpose, see definition of the controlled terminology below\nThe methodology used for enacting trial blinding.",
            "guidance": "Describe efforts to ensure that the investigational trial intervention(s) are as indistinguishable as possible. Plans for the maintenance of randomisation codes and appropriate blinding for the trial should be described. Procedures for planned (e.g. Interim Analysis), and unintentional (e.g. breach of procedure) breaking of randomisation codes should be provided. For unplanned but intentional actions (e.g. safety events), refer to Section 6.7.4 Emergency Unblinding at the Site.\nIf the trial allows for some investigators or other designated staff to remain unblinded (for example, to allow them to adjust investigational trial intervention), the means of maintaining the blinding for other investigators or staff should be explained. Measures to prevent unblinding by laboratory measurements or while performing study assessments, if used, should be described. ",
            "conformance": "Conditional: when blind trial ",
            "cardinality": "One to one",
            "relationship": "6.7.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.3 Blinding\nConcept: C189349",
            "repeating": "No",
            "ct": []
        },
        "Investigational Trial Intervention  ": {
            "name": "Investigational Trial Intervention  ",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the measures taken to ensure trial intervention compliance, including mandatory documentation to be filled out and the source data that will be used to document investigational trial intervention compliance.",
            "guidance": "Describe the measures to monitor and document participants\u2019 compliance with investigational intervention (e.g. study intervention accountability records, diary cards, or investigational intervention concentration measurements).\nList what documents are mandatory to complete (for example, participant drug log) and what source data/records will be used to document investigational intervention compliance. ",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.8",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.8 Investigational Trial Intervention \nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Description of Nonnvestigational Trial Intervention": {
            "name": "Description of Nonnvestigational Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the non-investigational trial intervention",
            "guidance": "As stated in Section 6, non-investigational interventions are products used in the trial but are not part of trial objectives and hence, are not investigational trial interventions. \nThe non-investigational trial intervention(s) may be described concisely in a table or in the following sections as applicable.",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "6.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9 Description of Nonnvestigational Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Background Trial Intervention": {
            "name": "Background Trial Intervention",
            "data_type": "Text",
            "definition": "C165822\nFor review purpose, see definition of the controlled terminology below\nMedicinal products that are administered to each clinical trial subject, regardless of randomization group, a) to treat the indication which is the object of the study, or b) required in the protocol as part of standard care for a condition that is not the indication under investigation, and is relevant for the clinical trial design. [After Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017]",
            "guidance": "Describe permitted background intervention(s), including administration and any conditions for use.",
            "conformance": "Conditional: when any background interventions are defined ",
            "cardinality": "One to one",
            "relationship": "6.9.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9.1 Background Trial Intervention\nConcept: C165822",
            "repeating": "No",
            "ct": []
        },
        "Other Noninvestigational ": {
            "name": "Other Noninvestigational ",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA non-investigational trial therapy that is different than the one(s) previously specified or mentioned.",
            "guidance": "If applicable, describe the use of any other non-investigational intervention, for example, challenge agents or diagnostics.",
            "conformance": "Conditional: when any other non-investigational interventions are defined",
            "cardinality": "One to one",
            "relationship": "6.9.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9.3 Other Noninvestigational Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Permitted Concomitant Therapy ": {
            "name": "Permitted Concomitant Therapy ",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nConcomitant therapy that is approved for use in the trial.",
            "guidance": "If applicable, describe any permitted concomitant therapy.",
            "conformance": "Conditional: when any permitted concomitant therapies are defined ",
            "cardinality": "One to one",
            "relationship": "6.10.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.10.2 Permitted Concomitant Therapy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Los to FollowUp": {
            "name": "Los to FollowUp",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe mitigation strategies to be employed for the loss or lack of continuation of a participant to follow-up, including the frequency by which follow-up occurs.",
            "guidance": "Describe how the trial will define how participants are lost to follow-up. In general, participants should be considered lost to follow-up only if they cannot be reached despite multiple attempts contact. Also describe approaches that will be used to minimise loss to follow-up, such as multiple, diverse methods to remain in contact with participants (e.g., telephone calls, texts, and emails to the participant) and how contacts will be recorded.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "7.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.3 Los to Follow-up\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Clinical Safety Laboratory Assessments": {
            "name": "Clinical Safety Laboratory Assessments",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial-related laboratory assessments and procedures related to participant safety.",
            "guidance": "",
            "conformance": "Conditional: when Clinical Laboratory Assessments are required",
            "cardinality": "One to one",
            "relationship": "8.4.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.4 Clinical Laboratory Assessments\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Timing for Reporting to Sponsor or Designee": {
            "name": "Timing for Reporting to Sponsor or Designee",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the timing window between trial related events and their reporting to the sponsor or designee.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type ",
            "ct": []
        },
        "Timing": {
            "name": "Timing",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the timing window between trial related events and their reporting to the sponsor or designee.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "9.2.1",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.1 Timing\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Followup": {
            "name": "Followup",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the procedures for follow-up, including the assessment tools that will be used to monitor an event and the duration of follow-up.",
            "guidance": "Specify the procedures for follow-up. Include the assessment tools that will be used to monitor the events and the duration of follow-up after appearance of the events.",
            "conformance": "Required ",
            "cardinality": "One to one ",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Follow-up\nConcept: CNEW",
            "repeating": "No ",
            "ct": []
        },
        "Adverse Events of Special Interest or state Not applicable": {
            "name": "Adverse Events of Special Interest or state Not applicable",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to define, measure, confirm, and report the occurrence of adverse events that are of special interest to the specific trial, or state not applicable.",
            "guidance": "",
            "conformance": "Required ",
            "cardinality": "One to one",
            "relationship": "9.2.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.4 Adverse Events of Special Interest\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Participants Whose Partners Become Pregnant": {
            "name": "Participants Whose Partners Become Pregnant",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to collect pregnancy data for a trial participant's partner, who becomes pregnant while the participant is in the trial.",
            "guidance": "",
            "conformance": "Conditional: ",
            "cardinality": "One to one",
            "relationship": "9.3.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.3.2 Participants Whose Partners Become Pregnant\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Statistical Method of Analysis": {
            "name": "Statistical Method of Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical model, hypothesis, and methods of analyses for each objective within the trial.",
            "guidance": "Describe the statistical analysis methods that will be used to evaluate the Secondary objective(s) and associated estimand(s) in Section 3.. Ensure that the statistical hypothesis/model/analysis (and corresponding assumptions) is aligned with the Secondary estimand(s). If there is more than one Secondary objective, present each objective as a level 3 heading and present each subsequent heading in Section 10.5 as a level 4 heading.\nFor each objective, state the null and alternative hypotheses, including the pre-planned type 1 error rate, or alternative criteria for evaluating whether the objective has been met, and relevant operating characteristics if appropriate. Describe the statistical model used and the factors that will be included (covariates and interactions) and any rules for handling these factors (for example, pooling of centres).\nIf modelling and simulation methods are to be used, please describe the model (inputs and outputs), the underlying assumptions, and the method of model fitting.",
            "conformance": "Conditional: when there is Secondary estimand",
            "cardinality": "One to one",
            "relationship": "10.5.X.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.5.1 Statistical Method\nConcept: CNEW",
            "repeating": "",
            "ct": []
        },
        "Handling of Data in Relation to Primary Estimands": {
            "name": "Handling of Data in Relation to Primary Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how data will be handled for the statistical analysis in line with the primary estimand.",
            "guidance": "For each intercurrent event of the primary estimand(s) (Section 3.1, Estimand(s) for the Primary Objective(s)), explain how data will be handled for the statistical analysis in line with the primary estimand. The handling of intercurrent events in statistical analysis should be aligned with the specific estimand strategies being used.\nThis section should describe with more detail the rationale and handling of the data rather than repeating the guidance from the preceding sections.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "\n",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
            "repeating": "",
            "ct": []
        },
        "Handling of Missing Data in Relation to Primary Estimand": {
            "name": "Handling of Missing Data in Relation to Primary Estimand",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how missing data associated with the primary estimand will be handled, including the rationale for the approach.",
            "guidance": "Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "\n10.4.X.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
            "repeating": "",
            "ct": []
        },
        "Handling of Data in Relation to Secondary Estimands": {
            "name": "Handling of Data in Relation to Secondary Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how data will be handled for the statistical analysis in line with the Secondary estimand.",
            "guidance": "For each intercurrent event of the Secondary estimand(s) (Section 3.1, Estimand(s) for the Secondary Objective(s)), explain how data will be handled for the statistical analysis in line with the Secondary estimand. The handling of intercurrent events in statistical analysis should be aligned with the specific estimand strategies being used.\nThis section should describe with more detail the rationale and handling of the data rather than repeating the guidance from the preceding sections.",
            "conformance": "Conditional: when there is Secondary estimand",
            "cardinality": "One to one",
            "relationship": "\n10.5.X.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:10.5.2 Handling of Data in relation to Secondary Estimand(s)\nConcept: CNEW",
            "repeating": "",
            "ct": []
        },
        "Handling of Missing Data in Relation to Secondary Estimand": {
            "name": "Handling of Missing Data in Relation to Secondary Estimand",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how missing data associated with the Secondary estimand will be handled, including the rationale for the approach.",
            "guidance": " Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach.",
            "conformance": "Conditional: when there is Secondary estimand",
            "cardinality": "One to one",
            "relationship": "\n10.5.X.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.5.3 Handling of Missing Data in Relation to Secondary Estimand\nConcept: CNEW",
            "repeating": "",
            "ct": []
        },
        "Analysis Associated with Exploratory Objectivess": {
            "name": "Analysis Associated with Exploratory Objectivess",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical model, hypothesis, and methods of analyses for each exploratory objective within the trial.",
            "guidance": "Describe any exploratory analyses, if applicable. Additional subsections could be created to describe the analyses, as needed. If there is no exploratory objective, indicate \u201cnot applicable\u201d",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.6 Analysis Associated with the Exploratory Objective(s),\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Consent for Rescreening": {
            "name": "Consent for Rescreening",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the consent requirements for participants in the event of screen failure and rescreening.",
            "guidance": "If participants can be rescreened, state whether the participant needs to complete a new consent. Screen failure and rescreening should be clearly defined in the protocol, with cross-reference to those definitions.",
            "conformance": "",
            "cardinality": "One to one",
            "relationship": "11.3.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3.1 Informed Consent for Rescreening\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Informed onsent for Use of Remaining Samples in Exploratory Research": {
            "name": "Informed onsent for Use of Remaining Samples in Exploratory Research",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the consent requirements for exploratory research using the remainder of mandatory samples. If applicable, this may include text in the original consent that address the use of remaining samples or additional text.",
            "guidance": "If participants will be asked to consent to optional exploratory research using the remainder of mandatory samples, describe the use of remaining samples for optional exploratory research.\nIf any exploratory research is planned and additional written consent regarding the use of remaining samples for exploratory research will be obtained, describe the consent process.",
            "conformance": "",
            "cardinality": "One to one ",
            "relationship": "11.3.2",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "Risk Management": {
            "name": "Risk Management",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of how potential risks and critical to quality factors associated with the trial will be handled.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.6",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.6 Risk Management\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "of Source Data": {
            "name": "of Source Data",
            "data_type": "Text",
            "definition": "C125442\nFor review purpose, see definition of the controlled terminology below\n",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one ",
            "relationship": "11.",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: 11. Source Data\nConcept: C125442",
            "repeating": "No",
            "ct": []
        },
        "CountryRegionSpecific Requirements": {
            "name": "CountryRegionSpecific Requirements",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of any country or region-specific requirements related to the trial but not related to individual items in the protocol.",
            "guidance": "Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (e.g., document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (e.g., by country/region-specific amendments or addenda).\nAn alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies.",
            "conformance": " If there is Country/Region-specific differences",
            "cardinality": "One to many",
            "relationship": "12.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country/Region-Specific Differences\nConcept: CNEW",
            "repeating": "Yes, repeatable for each Country/Region",
            "ct": []
        },
        "CountryRegionspecific Protocol Clarification": {
            "name": "CountryRegionspecific Protocol Clarification",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of any country or region-specific clarifications related to a protocol item.",
            "guidance": "Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (e.g., document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (e.g., by country/region-specific amendments or addenda).\nAn alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies.",
            "conformance": " if there is Country/Region-specific differences",
            "cardinality": "One to many",
            "relationship": "12.2 ",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country/Region-Specific Differences\nConcept: CNEW",
            "repeating": "Yes, repeatable for each country/region",
            "ct": []
        },
        "Prior Protocol Amendments": {
            "name": "Prior Protocol Amendments",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the protocol has not been amended, is the first protocol amendment, or a statement that the protocol has been amended previously. ",
            "guidance": "Choose the applicable statement below. For an original protocol that has not been amended, retain the first sentence below and delete the remainder of this entire section. \n{Not applicable. This protocol has not been amended.} \nOr\n{Not applicable. This is the first protocol amendment.} \nOr include the below as applicable.\n{This protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent.}",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Not applicable. This protocol has not been amended. (CNEW)\nOr\nNot applicable. This is the first protocol amendment. (CNEW) \nOr \nThis protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent. (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.3 Prior Protocol Amendment(s)\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Amendment Details Statement Response",
                    "definition": "A terminology value set relevant to the amendment details statement responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not applicable. This protocol has not been amended.",
                    "definition": "Not applicable. This protocol has not been amended."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not applicable. This is the first protocol amendment.",
                    "definition": "Not applicable. This is the first protocol amendment."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "{This protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent.}",
                    "definition": "{This protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent.}\n"
                }
            ]
        },
        "Approval Date ": {
            "name": "Approval Date ",
            "data_type": "Date",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date that the sponsor approved the version of the protocol, ",
            "guidance": "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first).",
            "conformance": "Conditional: if amendment",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Date",
            "business_rules": "Value Allowed: Yes\nRelationship: The Overview of Changes from each prior protocol amendment is {provided below} or <specify alternative location>}.\nConcept: CNEW",
            "repeating": "Yes, repeatable one table per amendment",
            "ct": []
        },
        " or  enrolled globallylocallyper cohort": {
            "name": " or  enrolled globallylocallyper cohort",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage. The numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage.",
            "guidance": "",
            "conformance": ": when there is an amendment",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "<# or %> enrolled <globally/locally/per cohort>",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
            "repeating": "Yes, reuse from the title page",
            "ct": []
        },
        " or ": {
            "name": " or ",
            "data_type": "Number",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
            "guidance": "N/A",
            "conformance": " if Original Protocol =No",
            "cardinality": "One to one",
            "relationship": "Amendment Details",
            "value": "Integer for Number or one decimal point for percent",
            "business_rules": "Value Allowed: Yes\nRelationship: \u201d\nConcept: CNEW",
            "repeating": "Yes, reuse from the title page",
            "ct": []
        },
        "specify alternative location ": {
            "name": "specify alternative location ",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nthe physical or virtual location of the date on which the sponsor approved the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: when a specify alternative location is selected",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Text Location where information can be found",
            "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
            "repeating": "Yes, reuse from the title page.",
            "ct": []
        },
        "amendment number": {
            "name": "amendment number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to uniquely identif a protocol amendment",
            "guidance": "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first).",
            "conformance": "Conditional: if amendment",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Text ",
            "business_rules": "Value Allowed: Yes\nRelationship: Overview of Changes from each prior protocol amendment is {provided below} or <specify alternative location>}.\nConcept: CNEW",
            "repeating": "Yes, repeatable one table per amendment",
            "ct": []
        }
    }
}